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Diabetes mellitus is a worldwide major concern associated with hyperglycaemia due to lack 
of insulin effects. Management of hyperglycaemia and diabetes associated complications 
relies on various strategies such as insulin injections and a host of oral anti-hyperglycaemic 
drugs. However, these therapies have limited efficacy, tolerability and significant side effects. 
Moreover, when glycaemic control is not achieved by a monotherapy, combination therapy is 
administered. Taken together, these challenges exert a major burden on health systems and 
facilities. Therefore, novel therapies with less undesirable effects and enhanced efficacy are 
under a constant evaluation. Recently, the anti-hyperglycaemic activity of vanadium 
complexes (IV) and (V) has received infinite attention for diabetes management.  
Accordingly, this study aimed to investigate the effects of  novel oxidovanadium complexes 
cis-[VO2(Hpybz)(pybz)] (1), (µ-O)[VO(Hpybz)(pybz).VO(Hpybz)(acac)] (2)  and 
[VO(Hpbyz)2SO4].H2O (3)   on glucose metabolism in vitro. The first objective was to 
investigate the effects of oxidovanadium complexes on glucose utilisation and mechanisms 
involved in liver and muscle cell lines. The second objective was to investigate the effects of 
oxidovanadium complexes on insulin secretion in pancreatic cell line.  
 
 
Materials and methods 
Liver (Chang), muscle (C2C12) and pancreatic (RIN-5) cell lines were cultured using a well-
established protocol in Eagle’s Minimal Essential Medium, Dulbecco’s Modified Eagle’s 
Medium and Roswell Park  Institute Medium 1640, respectively. Cell viability studies were 
carried in all cells. All doses of oxidovanadium complexes or standard drugs used in glucose 
utilisation and insulin secretion studies were extrapolated from preliminary studies.  For 
glucose utilisation studies, separate preparations of muscle and liver cell lines incubated with 
media containing 29 and 19 mmol/L of glucose, respectively were treated with 12.5, 25 and 
50 μg/mL of oxidovanadium complexes (1, 2 and 3). Dimethyl sulphoxide (0.1%) and insulin 
(4 μg/mL) or metformin (160 μg/mL) treated cells served as a negative and positive control, 
respectively. Furthermore, to examine the effects of combined treatment, some cells were 
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treated with lowest dose of oxidovanadium complexes combined with either insulin or 
metformin. Media glucose concentrations were measured after 0, 12, 24 and 48 h.  After 48 
hours, liver and muscle cells were harvested for measurements of glycogen and expressions 
of GLUT4 and glycogen synthase. For insulin secretion studies, separate preparations of 
pancreatic cells incubated with media containing 18 mmol/L of glucose were treated with 
12.5 μg/mL of oxidovanadium complexes (1, 2 and 3) and dimethyl sulphoxide (0.1%) 
treated cells served as a control. Media glucose and insulin concentrations were measured at 
12, 24 and 48 hours.  
 
Results  
All 3 oxidovanadium complexes (12.5, 25 and 50 μg/mL) had no apparent effects on cell 
viability in liver and muscle cells. However, for pancreatic cell lines, only lowest dose was 
not toxic. By comparison to the control, administration of oxidovanadium complexes 
significantly increased (p<0.05) glucose uptake after 48 h in both liver and muscle cell with a 
concomitant increase in glycogen concentrations. By comparison to the control, 
administration of oxidovanadium complex (2) significantly increased (p<0.05) glucose 
uptake as indicated by a decrease in media glucose (11.5±0.5 vs 7.8±1.0 mmol/mL) with a 
concomitant increase in insulin secretion (191.1±2.4 vs 255.0±2.1 pmol/L) by the pancreatic 
cell. Administration of oxidovanadium complexes combined with either insulin or metformin 
showed no apparent additive effects on glucose utilization and glycogen synthesis. 
Furthermore, administration of oxidovanadium complex (2) significantly increased (p<0.05) 
expressions of GLUT4 and glycogen synthase in muscle and liver cells, respectively.  
 
Discussion 
These results suggest that oxidovanadium complexes enhance glucose utilization and 
glycogen synthesis in both liver and muscle cells in vitro. The observed effects may be partly 
mediated via increased expression of GLUT4 and glycogen synthase. These observations 
extend the literature evidence; since various vanadium complexes have been shown to 
possess anti-hyperglycaemic effects. The increase in insulin secretion by pancreatic cells after 
oxidovanadium complex (2) administration cannot be explained by the present study. Taken 
together, these observations suggest that oxidovanadium complex (2) may have beneficial 




Oxidovanadium complexes enhance glucose metabolism in both liver and muscle cell lines. 
These results suggest that oxidovanadium complexes may exert a tight glycaemic control 
which is beneficial in diabetes management.  
 
Recommendations 
These observations highlight the necessity to further evaluate the effects of oxidovanadium 

























TABLE OF CONTENTS       PAGE NO 
 
Acknowledgements          i 
Plagiarism declaration        ii 
Declaration           iii 
Abbreviations          iv 
Abstract          viii 
          
Chapter 1-Literature review  1                                                      
   
1.1 Background         1 
1.2 Glucose homeostasis        2 
1.3 Glucose transporters        2 
1.4 The role of skeletal muscle and liver in glucose homeostasis  3 
1.5 Insulin effects         4 
1.6 Insulin mechanism        5 
1.7 Diabetes Mellitus        6 
            1.7.1 Classification of DM       7 
            1.7.2 DM complications       8 
 1.7.3 Aetiology of DM complications     11 
1.7.4 Conventional management of diabetes    14 
 1.7.5 Alternative strategies in diabetes management   16 
 1.7.6 Experimental diabetic models     17 
1.8 Justification of the present study      20 
1.9 Aims          20 
1.10 Objectives         20 
                                                       
 
Chapter 2-Materials and methods       21 
 
2.1 Materials         21 
        2.1.1 Chemicals and drugs       21 
2.2 Methods         22 
        2.2.1 Synthesis of oxidovanadium complexes    22 
xii 
 
        2.2.2 Experimental design       22 
        2.2.3 Cell culture protocol       24 
        2.2.4 Cell viability studies       24 
        2.2.5 Glucose utilization studies      25 
        2.2.6 Glycogen assay       26 
        2.2.7 Insulin secretion studies      26 
        2.2.8 Western blot analysis       27 
        2.2.9 Statistical analysis       28 
 
 
                                                     
Chapter 3-Results         29 
 
 
3.1 Synthesis of oxidovanadium complexes     29 
 
3.2 Cell viability         29 
3.2.1 Effects of oxidovanadium complexes     29 
 
3.2.2 Effects of oxidovanadium complexes combined with  29 
           insulin 
 
3.2.3 Effects of oxidovanadium complexes combined with  30 
           metformin 
 
3.3 Glucose utilisation        38 
3.3.1 Effects of oxidovanadium complexes     38 
 
3.3.2    Effects of oxidovanadium complexes 
combined with insulin      38 
  
 
3.3.3 Effects of oxidovanadium complexes 




3.4 Effects of oxidovanadium complexes on glycogen synthesis  46 
 
3.5 Effects of oxidovanadium complexes on insulin secretion   48 
 
3.6 Western blot analysis        50 
 
3.6.1 Glycogen synthase       50 
 
3.6.2 GLUT4        50 
 
                                                                     
  Chapter 4-Discussion        53 
  
 
  Chapter 5-Conclusions        61 
5.1 Conclusions         61 
5.2 Limitations         61 
5.3 Recommendations for future studies      61 
 
Chapter 6-References        62 
             
 
Chapter 7-Appendices        77 
 
 
LIST OF TABLES        
 
Table 1:  The effects of oxidovanadium complexes and combined  47 
           treatment on glycogen synthesis in liver and muscle cells 
 






LIST OF FIGURES  
 
Figure 1: Pathways involved in diabetes pathogenesis    13 
                   
Figure 2:  Summarized outline of the protocols used in the study  23 
 
Figure 3:  The effects of oxidovanadium complexes on cell viability  31 
             in liver cells  
 
Figure 4: The effects of oxidovanadium complexes on cell viability  32 
            in muscle cells 
 
Figure 5: The effects of oxidovanadium complexes on cell viability   33 
                         in pancreatic cells 
 
Figure 6: The effects of oxidovanadium complexes combined    34 
             with insulin on cell viability in liver cells  
     
Figure 7: The effects of oxidovanadium complexes combined    35 
      with insulin on cell viability in muscle cells 
 
Figure 8: The effects of oxidovanadium complexes combined   
     with metformin on cell viability in liver cells    36 
 
Figure 9: The effects of oxidovanadium complexes combined with  




Figure 10: The effects of oxidovanadium complexes on glucose   
             utilisation in liver cells      40 
 
Figure 11: The effects oxidovanadium complexes on glucose    
utilisation in muscle cells       41 
 
Figure 12: The effects of oxidovanadium complexes combined    
with insulin on glucose utilisation in liver cells   42 
 
Figure 13: The effects of oxidovanadium complexes combined   
with insulin on glucose utilisation in muscle cells   43 
 
Figure 14: The effects of oxidovanadium complexes combined    
with metformin on glucose utilisation in liver cells        44 
 
Figure 15: The effects of oxidovanadium complexes combined   
with metformin on glucose utilisation in muscle cells  45 
 
Figure 16: The effects of oxidovanadium complex (2) on glycogen    
synthase expression in liver cells                51 
 
Figure 17: The effects of oxidovanadium complex (2) on GLUT4    







LIST OF APPENDICES 
Appendix I:      Conference presentations 
(a) B Mkhwanazi, N Sibiya, M Serumula, R Myburg and C.T Musabayane. The effects 
of   Syzygium aromaticum -derived oleanolic acid on reactive oxygen species in the heart, 
liver and kidney of STZ-induced diabetic rats. Society for Endocrinology BES 2013,  18-
21 March           77 
 
 
(b) N. Sibiya, M. Serumula, R. Myburg and C.TMusabayane. Antioxidant effects of 
oleanolic acid in the liver, heart and kidneys of streptozotocin-induced diabetic rats. 
Physiological Society of Southern Africa 2013, 16-19 September.     78  
                          
(c) N Sibiya, M Serumula and C.T Musabayane. Evaluation of the effects of 
oxidovanadium 2-pyridylbenzimadizole (hpybz) on glucose metabolism in the liver and 
skeletal liver and skeletal muscle lines. Physiological Society 2014, 1 July.  79 
 
(d) N Mfayela, N Sibiya, M Serumula and C.T Musabayane. The effects of vanadium 
complexes on insulin secretion in pancreatic cell lines. College of Health Sciences Research 
Symposium 2014, 11-12 September.         80 
 
(e) Z Mvelase, N Sibiya, M Serumula and C.T Musabayane. The effects of vanadium on 
complexes combined with hypoglycaemic agents in the liver and muscle cell lines. College of 












           CHAPTER 1 
                                          INTRODUCTION/LITERATURE REVIEW 
 
1.1   Background 
 
Diabetes mellitus (DM) is a worldwide major concern associated with hyperglycaemia due to 
the lack of insulin effects. Insulin facilitates glucose uptake in the muscle and adipose tissue 
whilst promoting glycogen synthesis and inhibiting gluconeogenesis in the liver. These 
organs play a pivotal role in maintaining glucose homeostasis. Insufficiency of insulin or the 
hyporesponsiveness of the above-mentioned tissues to insulin results in hyperglycaemia 
which leads to the development of macro and microvascular complications. The management 
of hyperglycaemia and DM associated complications rely on various strategies such as 
insulin injections and a host of oral anti-hyperglycaemic drugs. However, these therapies 
have limited efficacy, limited tolerability and significant side effects. Therefore, novel 
therapies with less undesirable effects are under constant evaluation. Our laboratory is 
participating and contributing in a worldwide on-going research which seeks to develop novel 
anti-hyperglycaemic agents which include insulin formulations, bioactive plant compounds 
and anti-hyperglycaemic synthetic compounds.  Novel approaches are not only meant to 
broaden treatment availability, but also to manage DM more efficiently with less undesirable 
effects. Recently, the anti-hyperglycaemic activity of vanadium complexes (IV) and (V) has 
received attention.  Therefore, the focus of this study was directed to investigate the effects of 
oxidovanadium complexes on glucose metabolism in liver (Chang) and skeletal muscle 












1.2  Glucose homeostasis  
 
Glucose serves as a main source of substrate for energy production in the form of adenosine 
triphosphate (ATP). Therefore, glucose has a pivotal role in various cellular processes for 
homeostasis maintenance. In the body, glucose homeostasis is maintained by three highly 
coordinated processes. These processes include glucose absorption by the small intestine, the 
production or release of glucose by the liver and the utilisation of this monosaccharide nearly 
by most tissues (Aronson and Rayfield, 2000).  Some tissues such as brain are in a constant 
need of glucose supply, as a result hypoglycaemia can lead to seizures, loss of consciousness 
and irreversible neuronal cell damage.  On the other hand, some tissues are vulnerable to 
hyperglycaemia; in these tissues, high glucose concentrations have deleterious effects 
referred to as glucotoxicity. Glucotoxicity leads to nephropathy, retinopathy, cardiac and 
peripheral vascular diseases (Novella et al., 2001). Glucose acts as a main regulator of insulin 
production and secretion by beta (β)-pancreatic cells (Kaiser et al., 2003). Thus prolonged 
excessive amounts of glucose have a negative impact in β-pancreatic cell function.  Excessive 
glucose increases the release of insulin, which eventually causes a gradual depletion of 
insulin stores resulting in DM (Kaiser et al., 2003). Therefore, there is an imperative 
necessity to maintain blood glucose within narrow limits. Glucose is a hydrophilic molecule, 
as result glucose cannot passively diffuse across the hydrophobic lipid bilayer membrane. 
Thus, there are various proteins located on the cell membranes to facilitate glucose transport 
into the cells. 
 
1.3  Glucose transport 
 
There are two types of glucose transporters which facilitate glucose transport into cells. 
Glucose transporters are classified into two; sodium dependent glucose transporters (SGLTs) 
and glucose transport facilitators (GLUTS). To date, known and well documented SGLTs 
include 1, 2, 4 and 6, and each SGLT has a distinct feature or function. They are integral 
proteins in the cell membranes mediating glucose transport, with high affinity for glucose 
(Wright et al., 1994). This transport system mediates the transport for both glucose and 
sodium ions (Wright, 2001). The inward movement of sodium ions is favoured by 
concentration gradient of sodium; the membrane potential generated is coupled to glucose 
entry (Diez-Sampedro et al., 2000).  SGLT 1 is known to be a high affinity and low capacity 
sodium glucose transporter with sodium to glucose coupling ratio of 2:1. This co-transporter 
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is mainly found in intestines, heart and kidneys (Zhou et al., 2003). On the other hand, SGLT 
2 is known to have low affinity and high capacity, with sodium to glucose coupling ratio of 
1:1 (Mackenzie et al., 1994). SGLT 2 is ubiquitously expressed, however, there is high 
expression in the intestine and kidneys (Gerardi-Laffin et al., 1993).  
 
The human genome codes for 14 known GLUTS. Due to their amino acid sequence 
similarities and characteristics, GLUTS are divided into three subfamilies; Class 1 (1, 2, 3, 4 
and 14), Class 2 (5, 7, 9, and 11) and Class 3 (6, 8, 10 and 12) (Joost and Thorens, 2001). 
Both GLUT1 and 2 are highly expressed in DM, which lead to high glucose absorption by 
small intestine and re-absorption in the kidneys (Kahn, 2002). Thus, inhibition of these 
transporters is beneficial in DM management.  GLUT4 activity increases up to 20-folds when 
stimulated by insulin. In DM, GLUT4 expression is decreased and leads to inadequate 
glucose uptake by muscle and adipose tissue (Sheperd and Kahn, 1999).  Various anti-
hyperglycaemic agents have been shown to manipulate the glucose transport in muscle, 
adipose and liver to improve glucose homeostasis. 
 
1.4   The role of skeletal muscle and liver in glucose homeostasis  
   
As the main crucial detoxifying organ of the body, the liver plays a pivotal role in metabolic 
homeostasis and is a major site for synthesis, catabolism, storage and redistribution of 
carbohydrates, proteins, lipids as well as exogenous substances (Postic et al., 2004). In the 
liver, insulin stimulates glycogen synthesis by increasing glycogen synthase expression and 
inhibition of glycogen breakdown. Additionally, insulin also stimulates glycolysis and 
inhibits gluconeogenesis in the hepatocytes thus lowering blood glucose (Aronson and 
Rayfield, 2000). In the absence of insulin, glycogenesis is impaired, on the other hand 
gluconeogenesis is enhanced and as a result more glucose is released by the liver to the 
circulatory system through a bidirectional GLUT2, and worsens hyperglycaemia. The rate of 
gluconeogenesis is controlled principally by the activities of unidirectional enzymes such as 
phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase (FPase) and 
glucose-6-phosphatase (G6Pase) (Bechmann et al., 2012). PEPCK catalyses one of the rate 
limiting steps of gluconeogenesis, the conversion of oxaloacetate to phosphoenolpyruvate 
(PEP), while G6Pase catalyses the final step of gluconeogenesis, the production of free 
glucose from glucose-6-phosphate  (Postic et al., 2004). Insulin inhibits gluconeogenesis by 
suppressing the expression of PEPCK and G6Pase (Bechmann et al., 2012).  In the liver, 
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vanadium complexes such as vanadyl sulphate have been reported to inhibit glycogenolysis 
by inhibiting G6Pase and glycogen phosphorylase (Shehzad, 2013). In addition, vanadium 
has also been found to improve glucokinase and pyruvate kinase which have positive effects 
on glycogenesis. However, the effects of vanadium on gluconeogenesis are unclear. 
  
Unlike the liver, the muscle cannot regulate the release of glucose into circulation. However, 
the ability to rapidly increase glucose uptake is critical for maintenance of glucose 
homeostasis. In muscle, insulin stimulates amino acid uptake, protein synthesis, glucose 
uptake and incorporation of glucose into glycogen (Aronson and Rayfield, 2000). The muscle 
as well as adipose tissue expresses significant amounts of the GLUT4 which upon insulin 
stimulation, is translocated to the plasma membrane allowing glucose uptake (Bryant et al., 
2002). Vanadium complexes have been found to improve glucose homeostasis  by  promoting 
the activation of GLUT4 and  hence promoting glucose uptake in skeletal muscle (Shehzad, 
2013). In DM, the absence of insulin effects results in inadequate glucose uptake by muscle 
tissue which leads to hyperglycaemia. Studies have also reported that an increase in 
intramuscular fat content induces insulin resistance through generation of active fatty acid 
derivatives which can interfere with insulin signaling. 
 
1.5   Insulin effects 
 
Insulin is responsible for regulation of blood glucose homeostasis through promoting glucose 
utilisation by target tissues and storage in the form of glycogen in the liver. Insulin is a dimer 
made of alpha (α) and β chains which are joined together by disulphide bonds. This hormone 
is composed of 51 amino acids and is 5808 Da.  Insulin is synthesized by β-cells of the 
pancreas in the form of pro-insulin which is further modified to insulin (Annandale et al., 
2004). In addition to carbohydrate metabolism, insulin also stimulates lipid, protein 
anabolism and growth (Ringborg et al., 2010). Deficiency of insulin results in  muscle 
wasting and lipid breakdown due to activation of hormone sensitive lipase and inhibition of 
lipoprotein lipase (Shen et al., 2007). Insulin secretion is stimulated by high blood glucose 
and fatty acid. High blood glucose levels lead to depolarization of the β-cells due to 
activation of ATP-potassium (K
+
) channels.  Subsequent events include opening of calcium 
(Ca
2+
) channels which lead to secretion of insulin. Low levels of blood glucose or starvation 
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inhibit secretion of insulin. In addition, there are various hormones such glucagon and 
catecholamines which suppress insulin actions. Both glucagon and catecholamines promote 
hyperglycaemia and in DM high levels of these hormones worsens the condition. Bis-
maltolato vanadium complex has been shown to decrease glucagon levels in the pancreatic 
cells of STZ-induced diabetic rats. Due to DM, to date, there are agents that have the ability 
to enhance insulin secretion such as sulphonylureas. On the other hand, some drugs such as 
insulin glargine have the ability to extend insulin half-life. Immunohistological staining 
studies have shown elevated insulin in pancreatic cells with a concomitant increase in plasma 
insulin levels after bis-maltolato vanadium and vanadate pyrrolodine-N-dithiocarbamate 
administration, in vivo (Conconi et al., 2003) 
 
1.6  Insulin mechanism 
  
Insulin receptors (IR) are present particularly in adipose and muscle tissues.  Insulin receptors 
have two components, α components which are found in the cell membrane surface and  β 
components which are within the cell (Saltiel and Pessin, 2002). Insulin binds to α and 
activates β components. The activation of IR causes phosphorylation of two major 
downstream targets which are insulin receptor substrate 1 (IRS-1) and insulin receptor 
substrate 2 (IRS-2) (Cai and Dhe-Pagano, 2003). IRS-2 function is poorly understood, 
however, some studies have shown that IRS-2 is involved in lipid metabolism and mitogen 
activated pathway kinase (MAPK) signaling pathway. MAPK pathway signalling is 
important for DNA and protein synthesis which leads to cell proliferation. IRS-1, on the other 
hand is responsible for glucose metabolism. IRS-1 has various sites for tyrosine  and 
serine/threonine phosphorylation which are significant in the activity of IRS-1. Reduced 
insulin-stimulated phosphorylation has been observed in type 2 DM. IRS-1 phosphorlyation 
by tyrosine kinases activates phospho-inositol 3 kinase (PI3-K) which causes insertion of 
GLUT4  across the membrane in the muscle and adipose tissue (Engelman and Luo, 2006).  
GLUT4 then transport glucose into the cell (Annandale et al., 2004). P13-K also activates 
further pathways such as Akt. This pathway is involved in cell survival and also glycogen 
synthesis. Akt phosphorylates glycogen synthase 3-kinase (GS3-K) to activate glycogen 
kinase for glycogen synthesis in the muscle (Grimes and Jope, 2001; White, 2003). Defects in 
PI3-K have been reported also in type 2 DM, which lead to inadequate glucose uptake. Cells 
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using this transport system are said to be insulin dependent (Annandale et al., 2004). 
Recently, tyrosine phosphatases have been found to inhibit insulin sensitivity, thus inhibition 
of phosphatases may present a novel approach in overcoming insulin resistance. Studies have 
shown that vanadium has the ability to inhibit phosphatases thus increasing insulin sensitivity 
(Bhattacharyya and Alan, 2001). 
Despite the ability of vanadium to interact with insulin signaling pathways, vanadium has 
also been found to interact with other novel pathways to ensure adequate glucose uptake 
(Fantus and Tsiani, 1998; Medhi and Srivastava, 2005). Studies have reported a cytosolic 
protein-kinase which was activated 3-fold after vanadium administration in the muscle cell 
line (Shisheva and Shechter, 1991). The biological effects of vanadium which include 
glucose oxidation and lipogenesis were attributed to activation of cytosolic protein-kinase 
(Shisheva and Shechter, 1991). In addition, vanadium has also been shown to activate a non-
receptor protein in the cell membrane which activates PI3-K for glucose uptake and glucose 
metabolism (Shisheva and Shechter, 1991). Thus vanadium seems to utilise various pathways 
to ensure adequate glucose uptake, which may be of importance in the management of 
hyperglycaemia and DM associated complications. 
 
1.7 Diabetes mellitus 
 
 Approximately 3.2 million deaths caused by DM have been reported worldwide and of 
which the trend is expected to increase in future exerts a major burden in the health systems 
and facilities (Fazeli et al., 2013). In South Africa and other developing countries, reports 
indicate that the disease is amongst the leading cause of mortality and morbidity  (Abegunde 
et al., 2007; Mash et al., 2012). DM is a chronic metabolic disorder characterized by 
hyperglycaemia which is associated with development of both type 1 and 2 DM. 
Hyperglycaemia may result as a consequence of insulin insufficiency or insulin resistance. 
The insufficiency of insulin may be caused by exhaustion or dysfunction of the β-cells in the 
pancreas. Hyperglycaemia may also result as a consequence of insulin resistance which may 
be caused by hyporesponsiveness of target tissues such as muscle and adipose to insulin.  
Insulin promotes glucose uptake in the muscle and adipose tissue and also glucose storage in 
the liver through glycogen synthesis, thus maintaining glucose homeostasis. Therefore, the 
lack of insulin effects results in impaired glucose homeostasis  (Kristen, 2007). Sustained 
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hyperglycaemia results in the derangement of carbohydrate, lipids and protein metabolism 
which lead to DM pathological manifestations.  
1.7.1 Classification of diabetes mellitus 
 
The major types of DM are type 1 DM which is insulin dependent, type 2  DM which is non-
insulin dependent and gestational DM (Egede and Ellis, 2010).  To date, the effects of various 
vanadium complexes such as vanadyl sulphate and bis-maltolato vanadium have been studied  
in type 1 and 2 DM experimental models  (Medhi and Srivastava, 2005). Type 1 DM 
accounts for about 10% of all cases of diabetes and is often referred to as juvenile diabetes as 
this process takes place at some point during childhood or adolescence (Anabela et al., 2006). 
Type 1 DM results as a consequence of insulin deficiency which occurs due to the pancreatic 
β cells destruction through various mechanisms (Belle et al., 2001). One of the mechanisms 
involves the destruction of insulin producing cells as a consequence of autoimmunity (Belle 
et al., 2001). Studies suggest that chromosome 6 gene codes for human leukocyte antigen 
(HLA) which sensitizes the cells to destruction by autoimmunity (Belle et al., 2001). The 
initial presentation of type 1 DM is characterized by sudden onset of hyperglycaemia, often 
with ketoacidosis (Charpentier et al., 2003). Ketoacidosis may arise as a consequence of fatty 
acids utilisation as a substrate for energy production by various tissues. Without insulin to 
normalize blood glucose, the patient often  manifests with polyuria, polydipsia, polyphagia 
and weight loss (Saltiel and Kahn, 2001). In high blood glucose conditions, there is  
saturation of glucose transporters in the kidney which leads to glucosuria and polyuria, and as 
a consequence dehydration is often observed (John, 2014). Weight loss in DM is attributed to 
both dehydration and catabolism of lipids and proteins.  The absence of insulin has been 
shown to inhibit the satiety centre in the hypothalamus and thus such patients exhibit higher 
food consumption. In order to circumvent these manifestations, type 1 DM patients depend 
entirely on exogenous insulin. Therefore, any novel agent that mimics insulin actions is of 
therapeutic value in the management of type 1 DM. Previous studies have shown that 
inorganic vanadium complexes such as  sodium orthovanadate  exert  anti-diabetic effects in 
animal models of type 1 DM (Berhan and Habtewolde, 2012). However, there is an on-going 
controversy with regards to vanadium therapy in management of type 1 DM since vanadium 
has been shown to be catabolic (Berhan and Habtewolde, 2012). Interestingly, bis-maltolato 
vanadium complexes have been shown to decrease food consumption in STZ- induced 
diabetic rats, which is beneficial in DM management (Reul et al., 1999).  
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Type 2 DM which is also known as late onset DM results from various causes and accounts 
for about 90% of morbidity and mortality. Type 2 DM is considered as the most difficult type 
to manage efficiently due to various reasons. Over the years, establishing a proper type 2 
diabetic model has been difficult, thus there are still some gaps in the knowledge we have 
regarding type 2 DM.  At the beginning of the disease, insulin is usually sufficient to sustain 
glycaemic control. However, the target tissues such as muscle and adipose progressively lose 
sensitivity to insulin (Suzuki et al., 2003). There are several factors that sensitize individuals 
to type 2 DM. Sedentary life style and unhealthy diets increase the risk of type 2 DM, hence 
healthy diets and physical activities are recommended to the patients (Tessier et al., 2000). 
Obesity and high circulating levels of free fatty acids have been shown to trigger insulin 
resistance by interacting and causing defects in the insulin signaling pathways (Adilson et al., 
2008). Insulin resistance can occur either in the insulin receptor or downstream in the cascade 
(Samuel and Shulman, 2012). Disturbance in the insulin signalling pathway has deleterious 
effects since glucose uptake is impaired. Unlike type 1 DM which is managed by 
administering insulin, type 2 is usually managed by the use of various oral hypoglycaemic 
agents such as metformin which enhance insulin sensitivity in both muscle and adipose 
tissue.  Interestingly, reports have indicated that vanadium has the ability to increase insulin 
sensitivity in target tissues (Medhi and Srivastava, 2005). Studies have shown that oral 
vanadyl sulphate increases hepatic and peripheral insulin sensitivity in patients with type 2 
DM (Cohen et al., 2001).  Furthermore, type 2 DMis associated with obesity and catabolic 
effects of vanadium may be of significance in the management of type 2 DM.  
 
1.7.2   Diabetes mellitus complications  
 
DM complications are classified into macrovascular and microvascular complications. Both 
complications are associated with high morbidity and mortality. Macrovascular complications 
involve the aberrations of large vessels such as veins and arteries (Kota et al., 2012). The 
complications include atherosclerosis, hypertension and coronary heart diseases (Kota et al., 
2012). Treatment with inorganic and organic vanadium compounds has been shown to exert a 
wide range of cardiovascular-protective effects (Bhuiyan and Fukunaga, 2009). The central 
pathological mechanism in macrovascular disease is the process of atherosclerosis which 
leads to narrowing of arterial walls throughout the body (Fowler, 2008). In the development 
of atherosclerosis, oxidative stress results in the entrapment of oxidative low density 




which further form macrophages and foam cells (Fowler, 2008). These together with high 
levels of circulating free acid and adhesion molecules block vessels by forming plaques. In a 
study published in 1999, researchers at the Albert Einstein College of Medicine in New York 
compared the effects of vanadyl sulphate in moderately obese diabetic and non-diabetic 
people (Boden et al., 2000). The results showed that LDL cholesterol levels and oxidative 
status were reduced. Since vanadyl sulphate has been shown to reduce cholesterol levels, 
vanadyl sulphate together with other vanadium complexes may be beneficial in treating 
atherosclerosis and heart disease and may play an important role in reducing incidences of 
heart attacks (Bhuiyan and Fukunaga, 2009). Hypertension is also recognized as a 
macrovascular complication, sustained hypertension is associated with progression of both 
diabetic nephropathy and neuropathy. 
 
Microvascular complications involve aberrations in the small vessels such as capillaries. The 
complications include diabetic retinopathy, neuropathy and nephropathy. Angiogenesis has 
been hypothesized as the gateway to retinopathy and nephropathy (Kota et al., 2012). The 
effect of angiogenesis in neuropathy has not been well studied (Kota et al., 2012).  Vanadium 
complexes such as peroxovanadium have been found to exhibit anti-angiogenic properties in 
animal models (Doillon et al., 2000). The inhibition of angiogenesis by these complexes can 
be used in the prevention and treatment of diabetic retinopathy and nephropathy (Doillon et 
al., 2000). Therefore, this highlights the significance of vanadium complexes as an alternative 
method for the management of microvascular complications in DM. 
Diabetic retinopathy (DR) is the leading cause of visual disability and blindness in people 
with diabetes (Cade, 2008). Diabetic retinopathy is characterized by retinal vessel micro 
aneurysms, haemorrhages and oedema (Fowler, 2008). One of the primary changes in 
diabetic retinopathy involves loss of pericytes in retinal capillaries which may lead to 
vascular failure and chronic hypoxia (Maritim et al., 2002). Hypoxia is one of the major 
inducers of angiogenesis (Kota et al., 2012). Hypoxic conditions lead to the upregulation of 
hypoxia- inducible factor (HIF) and vascular endothelial growth factor (VEGF) which then 
promote the rapid formation of neovessels, resulting in exacerbated angiogenesis (Sone et al., 
1997). The sudden establishment of angiogenic vessels leads to leakiness and malfunctioning 
of vascular system (Kota et al., 2012). Vitreous hemorrhage is also observed in DR, due to 
leaking of newly formed blood vessels and jell-like substance which fills the centre of the eye 
thus impairing vision (Pang et al., 2011). Retinal detachment is also observed in DR, due to 
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abnormal new blood vessels which promote scar tissue growth, the latter pulls the retina 
away, ultimately causing spot floating vision (McHugh et al., 2011). Moreover, leaking and 
new growth of blood vessels interrupt the fluid flow in the eyes and this causes the pressure 
to accumulate, in severe cases this damages the optic nerve which leads to permanent 
blindness. The underlying mechanism of DR is hyperglycaemia and the ability of vanadium 
to achieve glycaemic control may have beneficial effects in alleviation of DR. Studies have 
reported that oral vanadyl sulphates alleviate cataracts in DM (Bosia et al., 2000). 
In clinical practice, diabetic neuropathy (DNE) is defined as signs and symptoms of 
peripheral nerve dysfunction in a diabetic patient where other causes of peripheral nerve 
dysfunction have been excluded. DNE has caused more hospitalization of DM patients than 
other complications, with half of the patients having some degree of the disease such as 
polyneuropathy and ormononeuropathy (Won et al., 2012). The prevalence of DNE has been 
found to be 66% and 59% for type 1 and type 2 DM, respectively (Kastenbauer et al., 2004). 
This complication is heterogeneous by symptoms and signs, risk factors, underlying 
mechanism and pathologic alterations. Mono and polyneuropathies, plexopathies and 
radiculopathies are observed in DNE (Dyck and Sinnreich, 2003). Autonomic neuropathy has 
been considered irreversible and life threatening since there is high risk of mortality. 
However, some studies have shown that cardiac denervation regresses with high glycaemic 
control (Stevens et al., 1999). For both prevention and therapeutic purposes, intense 
glycaemic control has been recommended. Early detection of hyperlipidaemia and 
hypertension, cessation of smoking and alcohol consumption may help in prevention and 
delaying the progression of DNE (Vinik, 2010).  
 
Diabetic nephropathy (DN) is the leading cause of renal failure in USA (Gordois et al., 
2004). DN is amongst the leading cause of mortality and morbidity for both type 1 and type 2 
DM (Thomson et al., 2009). Most patients experience the condition before they are 
diagnosed. However, the false assumptions may be made since proteinuria may be due to 
renal infection, exercise and haematuria (Thomson et al., 2009). Clinical hallmarks of DN 
include increased albumin excretion and declined glomerular filtration rate, both of which are 
associated with high blood pressure (Mogensen, 2003). These functional changes in the 
kidney occur as a consequence of structural changes which include the thickening of 
glomerular basement membrane, mesangial cell expansion and loss of podocyte, extracellular 
matrix deposition, glomerulosclerosis and tubulorinterstitial fibrosis. The ability of vanadium 
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complexes to lower blood glucose and also to act as antioxidants may be beneficial in both 
prevention and management of diabetic nephropathy.  
 
1.7.3   Aetiology of DM complications 
 
Sustained hyperglycaemia results in derangement of glucose metabolism, especially in those 
tissues which are insulin independent such as kidneys, retina and nerves. As described in the 
preceding paragraphs, these tissues are highly susceptible to hyperglycaemia due to the 
activation of four major pathways which act together in the establishment of DM 
pathogenesis. These metabolic pathways involve advanced glycation end products (AGEs), 
polyol, protein kinase C (PKC) and the hexosamine pathway as illustrated in figure 1. The 
anti-hyperglyaemic and antioxidant effects of vanadium may be beneficial in declining the 
activation of these pathways. 
 
The formation of AGEs is among the irreversible changes particularly in the kidney that 
occur as a result of hyperglycaemia (Ahmed, 2005). At high blood glucose concentrations 
there is an induction of non-enzymatic reaction between glucose and free amino acids (Singh 
et al., 2001). The interaction between glucose and amino acids results in Schiff-base 
formation, thereafter Amadori products. Subsequent rearrangements and reactions lead to 
formation of irreversible compounds known as AGEs (Singh et al., 2001). AGEs have a 
varying range of chemical, cellular and tissue effects through changes in charge, solubility 
and conformation.  Extracellular matrix proteins are highly susceptible to AGE modification. 
This results in structure and function alterations, for example, collagen glycation results in 
inter and intramolecular crosslinks which alters structure and increase resistance of collagen 
to proteolytic digestion. Moreover, AGEs accumulation has been found to increase the 
production of reactive oxygen species (ROS). The use of AGEs inhibitor (amminoguadine) 
has been found to alleviate AGEs associated complications in DM (Kelly et al., 2001). 
Moreover, an intense glycaemic regulation by various conventional treatments, especially at 
the early stage of DM, delays AGEs formation. In this regard, vanadium has been shown to 
possess both hypoglycaemic and antioxidants effects and, as a result vanadium may 




The polyol pathway has been shown to be involved in diabetic complications, particularly in 
microvascular damage in non-insulin sensitive tissues such as the lenses, peripheral nerves 
and the glomerulus (Dunlop, 2000). The polyol pathway is an alternative pathway activated 
by high intracellular glucose through aldose reductase (AR).  Glucose is converted to sorbitol 
which is a highly osmotic active molecule. The conversion of glucose to sorbitol is facilitated 
by AR in a nicotinamide adenine phosphate (NADPH) dependent reaction.  NADPH is 
known to be the universal hydrogen donor and responsible for the re-generation of the 
biological active glutathione which is an important antioxidant. Since polyol pathway 
consumes large quantities of NADPH levels, this results in impaired glutathione re-synthesis 
which ultimately causes redox imbalances leading to oxidative stress (Lorenzi, 2007). On the 
other hand, sorbitol accumulation activates sorbitol dehydrogenase which converts sorbitol to 
fructose (Lal et al., 1997).  Excessive levels of fructose are associated with high production 
of ROS through non enzymatic glycoxidation of proteins and lipids (Roger et al., 2003). 
Vanadium has been shown to inhibit AR activity in diabetic rat model in vivo (Lei et al., 
2014). 
 
Protein Kinase C (PKC) is a group of enzymes of the cyclic adenine monophosphate (cAMP) 
dependent protein kinase (AGC) family. PKC plays a pivotal role in many cellular functions 
and affects many signal transduction pathways (Alexandra and Newton, 2000).   There are 
multiple isoforms of PKC that function in a wide variety of biological systems. The well-
documented form of PKC (cPKC) isoforms include PKC-α, -β1, -β2, and -γ. These isoforms 
are activated by diacylglycerol (DAG) and ROS such as hydrogen peroxide (H2O2) that is 
generated in the polyol pathway (Alexandra and Newton, 2000). In DM, many abnormal 
vascular and cellular processes including endothelial dysfunction, vascular permeability, 
basement membrane thickening, extracellular matrix  (ECM) expansion and enzymatic 
activity alterationsare attributed to multiple PKC isoforms (Koya and King, 1998). Since 
PKC pathway descends from hyperglycaemia and ROS, intense glycaemic control by 
vanadium may attenuate hyper activation of PKC.   
 
Previous studies have suggested that the hexosamine pathway is implicated in diabetic 
nephropathy.  Under normal conditions glucose enters the glycolytic pathway where most of 
glucose is metabolized to pyruvate through glycolysis. However, a small quantity of fructose 
6-phosphate from glycolysis is converted to glucosamine-6-phosphate, a reaction catalyzed 
by glutamine: fructose-6-phosphate amidotransferase (GFAT). This results in the formation 
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of uridine diphosphate-N-acetylglucosamine. Uridine diphosphate-N-acetylglucosamine 
serves as a building block for glycosyl side chains of various proteins (Sayeski and Kudlow, 
1996). In DM, the rate through which fructose-6-phosphate is formed is elevated, leading to 
increased levels of uridine diphosphate -N-acetylglucosamine which results in increased 
formation of O-glycosylated proteins (Haltiwanger et al., 1998).  O-linked glycosylation of 
proteins leads to the induction of plasminogen activator inhibitor-1 (PAI-1) (Howard et al., 
2002). In DM, PAI-1 results in the accumulation of extracellular membrane proteins in the 
glomerular mesangium (Goldberg, 2000; Lee et al., 2005). To date, no studies have been 
undertaken to investigate the effects of vanadium on the hexosamine pathway. The ability of 















                                                    Diabetes complications 
 
Figure 1: The diagram illustrates the pathways involved in the pathogenesis of diabetes 
mellitus. The activation of these pathways progressively alters cellular functions through 

































1.7.4   Conventional management of diabetes 
 
To date, there are numerous therapeutic strategies used to manage diabetes since there are 
various pathogenic processes involved. Therapeutic agents used in DM treatment range from 
anti-hyperglycaemic agents, anti-hypertensive agents, anti-coagulant, anti-inflammatory and 
antioxidants. Thus management of DM and associated complications proves to be more 
complicated and challenging.  The main causal link of DM is hyperglycaemia, therefore the 
primary intervention targets to maintain euglycaemia. Various anti-hyperglycaemic agents 
have been shown to maintain normal glycaemia and alleviate DM associated insults. In 
addition to exogenous subcutaneous insulin injections, there are four conventional classes of 
oral anti-hyperglycaemic drugs. These drugs act at different target organs to achieve their 
desirable effects. These classes of drugs include biguanides, sulphonylureas, α-glucosidase 
inhibitors and thiazolidinediones (TZDs) which can be administered as monotherapy. 
However, when the oral anti-diabetic monotherapy does not achieve glycaemic goal, the 
combination therapy is implemented. Despite the availability of these drugs, the evaluation of 
promising novel agents is continuous and vanadium based compounds are among these 
agents (Medhi and Srivastava, 2005). 
 
 Insulin administered for DM treatment is obtained from pork pancreas or is made chemically 
identical to human insulin by recombinant DNA technology or chemical modification of pork 
insulin (Retnakaran et al., 2004). Insulin is available in rapid, short, intermediate and long 
acting types that may be injected separately or mixed (Retnakaran et al., 2004). However, this 
form of insulin administration can often be embarrassing and painful (Retnakaran et al., 
2004).  On average, the type 1 diabetics will administer between 5-6 injections per day. 
Importantly, continuous insulin injection progressively decrease receptor sensitivity and can 
result in insulin resistance (Uruska et al., 2014). Even with these measures, the daily 
necessity for several insulin injections can be painful both physically and mentally. For these 
reasons, the development of a new class of pharmaceuticals for treatment of DM would be 
extremely desirable. Vanadium has been reported to mimic insulin actions both in vivo and in 
vitro (Medhi and Srivastava, 2005). 
 
Biguanides class includes drugs such as metformin, buformin and phenformin.  To date, 
metformin is the only drug belonging to this class  available for management of DM (Correia 
et al., 2008). Metformin utilizes three mechanisms to maintain normal glucose levels. These 
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mechanisms include gluconeogenesis suppression in the liver, intestinal glucose absorption 
inhibition and peripheral glucose uptake stimulation in the presence of insulin (Ohiraa et al., 
2007).  In addition, metformin has been reported to decrease glycohaemoglobin and improves 
both fibronolytic activity and lipid profile. Metformin therapy appears to be beneficial in  
type 2 DM patients since no weight gain has been reported in DM patients (Seufert et al., 
2004). Metformin administration is however, associated with diarrheoa and poor intestinal 
absorption of vitamin B complexes (Adams et al., 1993).  Buformin and phenformin were 
withdrawn since they were associated with lactic acidosis (Misbin et al., 1998).  Metformin-
vanadium derivatives have, however, been evaluated and [VO (metformin)2] H2O has been 
shown to improve glycaemic control (Conconi et al., 2003). 
 
Sulphonylurea compounds continue to be the mainstay therapy for type 2 DM and have been 
available nearly half a century (Kar and Holt, 2008). Currently, glibenclamide is one of the 
sulphonylureas available for DM treatment. Glibenclamide  achieves glycaemic goal through 
stimulation of insulin release by the β-pancreatic cells (Hu et al., 2001). Sulphonylureas exert 
their effects by activation of ATP-dependent K
+
 channels, which allows depolarization of the 
cells, leading to insulin secretion (Fuhlendorf et al., 2001).  Despite their beneficial feature, 
sulphonylureas are associated with cardiovascular complications since they have been 
reported to impair myocardial blood flow and they also elicit proarryhthmic effects (Smits 
and Thien, 1999; Garratt et al., 2000). 
 
TZDs include anti-diabetic medications such as rosiglitazone, troglitazone and pioglitazone 
(Lebovits, 2002).  The TZDs are insulin sensitizers which bind to peroxisome proliferator-
activated receptor gamma (PPR γ) followed by elevated GLUT4 expression and glucose 
uptake (Saltiel and Olefsky, 2000). TZDs have also been shown to inhibit gluconeogenesis in 
the liver (Edgerton et al., 2009). Despite anti-hyperglycaemic effects, TZDs have been 
associated with weight gain in DM patients. Increased weight gain is attributed to reduction 
of leptin levels during TZDs treatment (Brakis et al., 2002; Nissen and Wolski, 2007). This 
feature of TZDs has harmful implications and has been documented in both experimental 
diabetes and human studies.  
 
Some anti-diabetic medications such as alpha-glucosidase inhibitors act primarily on the 
gastrointestinal tract, inhibiting starch hydrolysis and thus delaying glucose absorption 
(Kamawori et al., 2009). The compounds like voglibose, miglitol and acarbose inhibit various 
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enzymes of the α-glucosidase group (sucrase, maltase, isomaltase and glucoamylase). The 
membrane-bound enzymes in the brush border of the small intestine hydrolyze 
oligosaccharides and disaccharides to glucose (Kamawori et al., 2009). The hypoglycaemic 
potency of these drugs is less than that of biguanides and sulphonylureas (Moritoh et al., 
2009). The side effects of these drugs include mild pain, diarrhoea and flatulence (Chiasson 
et al., 2002). Taking into considerations the burden exerted by DM in health care systems and 
also the inability of conventional therapies to manage diabetes efficiently, there is a necessity 
to further search for alternative strategies in the management of DM. One of these strategies 
involves evaluation of various vanadium compounds for diabetes management.  
 
1.7.5   Alternative strategies for diabetes management 
Literature has documented a variety of alternative strategies in the management of DM. 
Various medicinal plants (crude extracts and bioactive compounds) have been reported to 
have anti-diabetic properties (Musabayane et al., 2005; Ugochukwu and Babady, 2008; Wang 
et al., 2010). In addition to natural medicinal products, there is also a continuous search and 
evaluation of several synthetic compounds, including various classes of vanadium complexes 
(Berhan and Habtewolde, 2012). Vanadium is a trace element which exists in a variety of 
oxidation states (+1 to +6) (Rehder, 2003). In the body, vanadium exists in low quantities 
with highest concentrations found in the liver, kidney and bone. Reports indicate that insulin-
sensitive tissues such as the liver and adipose metabolize vanadium more quickly compared 
to other tissues such as bone (Thompson et al., 2009). Vanadium ions cannot easily diffuse 
through the lipid bilayer; hence vanadium is not easily absorbed in the small intestine. 
However, vanadium is a highly flexible mineral and can form co-ordination complexes with 
ligands which can allow greater permeability of vanadium. Since the 1980’s, the 
hypoglycaemic effects of vanadium complexes in experimental diabetes have been reported 
together with the mechanisms relevant to both glucose and lipid metabolism (Medhi and 
Srivastava, 2005). Reports indicate that vanadium complexes (+4) and (+5) possess potent 
anti-diabetic insulin-like effects (Thompson et al., 2009). Various vanadium complexes have 
been shown to promote glucose uptake, glucose oxidation and glycogen synthesis (Reul et 
al., 1999). 
 
Depending on the nature of ligand, vanadium complexes can be divided into inorganic and 
organic complexes. Inorganic vanadium such as vanadyl sulphates and sodium orthovanadate 
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complexes were among the first to be investigated in DM and were shown to have promising 
anti-diabetic effects (Reul et al., 1999). Irrespective of their promising anti-diabetic 
properties, some inorganic vanadium complexes are associated with toxic effects such as 
diarrhoea, decreased fluid and food uptake, dehydration and reduced body weight gain (Reul 
et al., 1999). Thus, there is urgency in continuously developing new non-toxic and more 
potent vanadium complexes analogues. Furthermore, vanadium also has the ability to utilise 
other non-insulin pathways to lower blood glucose (Medhi and Srivastava, 2005). There is 
also an interesting growing body of evidence indicating that this class of metallo-
pharmaceuticals requires organic biological active ligand systems to provide stability and 
promote bioavability of the metal complex. Consequently, finding an appropriate organic 
ligand system may enhance the potency and circumvent the downfalls of vanadium salts. To 
date, there are various organic vanadium complexes such as vanadyl acetylacetonate, bis-
maltolato oxovanadium and vanadyl 3-ethylacetylacetonate which have been shown to exert 
anti-diabetic effects with minimal toxic effects as compared to inorganic vanadium 
complexes (Reul et al., 1999). Therefore, a continuous search for an appropriate ligand 
system is significant. 
2-pyridylbenzimidazole (Hpybz) is one of the well-established promising heterocyclic 
ligands which have been shown to also have an array of biological activities such as 
antimicrobial, antibacterial and anti-diabetic activities. Theoretically, an appropriate fusion of 
Hpybz with vanadium complex may have an additive effect in glucose lowering capacity thus 
improving the therapeutic value of vanadium.  Since the causal link of DM and associated 
insults is hyperglycaemia, the ability of a novel agent to efficiently lower glucose or facilitate 
glucose uptake is of importance in the therapy of the disease. 
 
1.7.6  Experimental diabetic models 
 
There are various diabetic models used to study DM related pathology and also to investigate 
the effects of various therapeutic modalities in management of DM. Experimental diabetes 
studies can be conducted in vivo and in vitro using animals and cell lines, respectively. 
Although both do not perfectly mimic human diabetes, they are valuable tools for evaluating 
novel anti-diabetic agents. There are various in vivo diabetic models, which include surgical 
diabetes, chemical induced and genetically engineered diabetes models. Surgical models 
involve removal of pancreas and have limitations. Limitations of surgical models include, 
18 
 
high degree of technical expertise required, post-operative analgesia and antibiotics 
administration and pancreatic enzymes supplementation (Masiello, 2006). The majority of 
documented studies in the field of experimental diabetes between 1996 and 2006 employed 
chemical induced-diabetes models. Streptozotocin and alloxan are the most frequently 
utilized drugs to induce diabetes (Federiuk et al., 2004). These two drugs selectively destroy 
β-pancreatic cells, which allow the study of various aspects of the disease (Mythili et al., 
2004). The diabetogenic actions of these drugs are exerted when administered intravenously, 
intraperitoneally and subcutaneously (Federiuk et al., 2004). The dose of these agents 
necessary to induce diabetes depends on the animal species, route of administrations and also 
nutritional status. Various vanadium complexes have been investigated using chemically 
induced-diabetic models. However, biological tests in whole animal have been found to be 
expensive, time consuming and have a limited sensitivity to differentiate between structurally 
similar compounds. These limits drive researchers to prior conduct in vitro studies using cell 
lines models before using animal models. 
 
Cell culture is a process where cells are grown under controlled conditions which can be 
easily manipulated and analysed (Li et al., 2004). Cell culture studies are the precursor to in 
vivo animal studies and help to elucidate various mechanisms of various therapeutic 
compounds and also to determine whether significant cytotoxicity exists for a particular given 
compound (Li et al., 2004). Therefore, cell culture is essential for biomedical research which 
include medicine, cell metabolism, genetic engineering and molecular biology  (Dunham and 
Guthmiller, 2008). Cell lines have been widely utilised in the field of cell metabolism, 
particularly evaluating the effects of various anti-diabetic agents. An anti-diabetic agent can 
affect various components of glucose metabolism and homeostasis including insulin 
secretion, glucose absorption by the small intestine, glucose storage or release by the liver, 
glucose uptake by muscle and adipose tissue and glucose re-absorption by the kidney. 
Therefore, appropriate cell lines allow studying and evaluating the effects of anti-diabetic 
agents on various isolated aspect of glucose homeostasis.  
 
There are various cell lines utilised as glucose utilisation models to determine the ability of a 
given compound in promoting and inhibiting glucose uptake. These models also allow 
researchers to monitor glucose utilisation and associated molecular events over time. 
Literature has documented various cell lines which have been used with adipose, muscle and 
liver lines being widely employed (Verma et al., 2004). Adipose tissue and skeletal muscle 
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are the key contributors to insulin resistance and hyperglycaemia. With recent advances, 
pathways related to glucose metabolism and insulin resistance can be successfully studied in 
the cell lines of adipose tissue such as murine 3T3-L1 cells and the skeletal muscle cell lines 
such as L6 engineered and C2C12 (Karalee et al., 2001; Yen et al., 2014). The muscle cell 
line (C2C12) is  an immortal and adherent cell line of mouse skeletal myoblasts  and  was 
originally derived from satellite cells of  mouse’s thigh muscle (Diel et al., 2008). This cell 
line differentiate well into myocytes under appropriate cell culture conditions (Diel et al., 
2008). C2C12 cell line is adherent cell line and grows as undifferentiated myoblasts in 
growth media. C2C12 cell line also expresses significant amounts of GLUT4 and glycogen 
synthase, therefore, C2C12 is a significant tool in studying the effects of a given compound 
on glucose uptake  (Karalee et al., 2001; Yen et al., 2014).  C2C12 cell line was chosen in the 
study to determine the effects of oxidovanadium compounds on glucose uptake, glycogen 
synthesis and GLUT4 expression. 
 
There are various liver cell lines employed in biological science and pharmaceutical industry. 
These cell lines include hepatocyte derived human transformed cell line (HepG2) and Chang 
cell line. Chang liver cells are immortalized non tumour cells derived from normal liver 
tissue of a mouse. Chang cell line, like other cell lines, are termed "immortal", thus they can 
divide in an unlimited number of times in a laboratory cell culture plate as long as 
fundamental cell survival conditions are met (Strick-Marchand and Weiss, 2003). Chang cells 
are also adherent cells and grow as undifferentiated hepatoblasts in growth media (Strick-
Marchand and Weiss, 2003). Furthermore, Chang cells are significant tools in assessing the 
effects of a given compound on glucose utilisation, glycogen synthesis as well as toxicity 
(Nadu, 2007; Ventera et al., 2008). Therefore, the Chang cell line was chosen in this study to 
determine the effects of oxidovanadium complexes on glucose uptake, glycogen synthesis 
and glycogen synthase expression. 
 
Recent advances provide opportunities to establish and improve various appropriate cell lines 
to facilitate studying mechanisms of both insulin secretion and cell dysfunction (Zhao et al., 
2005). To date, there are various insulin secreting cell lines, and widely used cell lines 
include rat insulinoma (RIN-5) (Poitout et al., 1996).  The RIN-5 cell line was derived from a 
radiation induced transplantable rat islet cell tumour. RIN-5 cell line mainly secrete insulin, 
small amounts of glucagon and somatostatin (Fernández-Millán et al., 2014). The behaviour 
of these cells, however, do not perfectly resemble cell physiology of β pancreatic cells, 
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nonetheless, they are extremely significant tools for the evaluation of drugs on insulin 
secretion together with associated molecular events (Fernández-Millán et al., 2014). 
Therefore, RIN-5 cell line was chosen in the study to determine the effects of oxidovanadium 
complexes on insulin secretion. 
 
1.8  Justification of the present study 
 
The literature evidence described in the preceding sections indicates that numerous vanadium 
compounds have potential in the management of diabetes. Of interest in this study, were the 
effects of oxidovanadium complexes on glucose metabolism in muscle and liver cell lines 
and insulin secretion by pancreatic cell lines. The outcome of the study may justify further 
evaluations of various potential vanadium complexes in the management of diabetes 
 
1.9  Aims 
 
The overall aim of the study was to investigate the effects of oxidovanadium complexes on 
glucose metabolism in the liver (Chang) and skeletal muscle (C2C12) cell lines.  The other 
aim was to evaluate the effects of oxidovanadium complexes on insulin secretion in 
pancreatic (RIN-5) cell line.  
 
1.10 Objectives 
The aims of this study were achieved by: 
i. synthesis and characterization of  novel oxidovanadium complexes 
i.  analysis of cytotoxic effects of oxidovanadium complexes using a luminescent-based 
cell viability assay 
ii.  determination of glucose utilisation in liver and muscle cells using a glucometer 
iii.  analysis of glycogen synthesis in liver and anthrone-based glycogen assay 
iv.  determination of insulin secretion using ELISA 






MATERIALS AND METHODS 
 
2.1  Materials 
 
2.1.1  Chemicals and drugs 
 
Chemicals and drugs were sourced as follows: 
dimethyl sulphoxide (DMSO), Tris-HCL, glycerol, Tris-base, glycine, sodium dodecyl 
sulphate (SDS), vanadyl sulphate, bovine serum albumin (BSA), phosphate buffered saline 
(PBS), anthrone, dioxovanadium (VO2), acetyl acetone oxovanadium (VO (acac)2), sulphato 
oxovanadium (VOSO4), Hpybz, ammonium vanadate, mercapthoethanol, bromophenol blue 
and Tween 20 ( Sigma-Aldrich, St Louis, Missouri, USA);  
 
Dulbecco’s Modified Essential Medium (DMEM), Eagle’s Minimum Essential Medium 
(EMEM), Roswell Park Memorial Institute Medium (RPMI) 1640, L-glutamine, 
penicillin/streptomycin (Pen/Strep), foetal calf serum (FCS) and trypsin (Highveld 
Biological, Johannesburg, South Africa);  
 
methanol (MeOH), ethanol, sucrose, sodium chloride (NaCl), sodium sulphate (NaSO4), 
potassium hydroxide (KOH), potassium chloride (KCl), dithiothreitol, glycerol (Merck 
chemicals, Johannesburg, South Africa);  
 
insulin (NovoRapid Pen Refill, Novo Nordisk Pty Ltd, Sandton, South Africa) and  
 
GLUT4, glycogen synthase, β actin and horse radish peroxidase (HRP) coupled antibodies 
(Abcam, Cambridge, United Kingdom).  




2.2  Methods  
2.2.1   Synthesis of oxidovanadium complexes  
The synthesis of oxidovanadium complexes (1, 2 and 3) was conducted in Dr I Booysens’ 
laboratory. The oxidovanadium complexes, cis-[VO2(Hpybz)(pybz)] (1), (µ-
O)[VO(Hpybz)(pybz).VO(Hpybz)(acac)] (2)  and [VO(Hpbyz)2SO4].H2O (3) were 
synthesized from the 2:1 molar ratio reactions of the ligand 2-pyridylbenzimidazole (Hpbyz) 
with the respective metal precursors, ammonium vanadate, vanadyl (IV) acetylacetone and 
vanadyl (IV) sulphate as reported by Booysen et al (2013) (Booysen et al., 2013). The 
complexes were characterized by the following conductance measurements; UV/Vis, nuclear 
magnetic resonance (NMR), electron spin resonance (ESR) and infrared resonance (IR) 
spectroscopy as well as single crystal X-ray diffraction.  
 
2.2.2   Experimental design  
The study was divided into 3 series. First series investigated the effects of oxidovanadium 
complexes (1, 2 and 3) on cell viability in liver, muscle and pancreatic cell lines. Second 
series investigated the effects of oxidovanadium complexes (1, 2 and 3) on glucose uptake, 
glycogen synthesis and expressions of GLUT4 and glycogen synthase in liver and muscle cell 
lines.  Lastly, third series investigated the effects of oxidovanadium complexes (1, 2 and 3) 
on insulin secretion in pancreatic cell line. An outline summarizing the experimental 



































Figure 2: Summarized outline of protocols used in the study. The effects of oxidovanadium 
on cell viability were investigated in liver, muscle and pancreatic cell lines. Subsequently, the 
effects of oxidovanadium complexes on glucose utilisation were monitored in liver and 
muscle cell lines, followed by biochemical parameters analysis. The effects of 
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2.2.3   Cell culture protocol 
 
The cell lines used in the study were kindly donated by Dr Christo J.F. Muller from the 
Diabetes Discovery Platform at the South African Medical Research Council (MRC), Cape 
Town, South Africa. Cell culture studies were conducted using a well-established protocol 
(Czifra et al., 2006). Briefly, DMEM, EMEM and RPMI for culturing muscle (C2C12), liver 
(Chang) and pancreatic (RIN-5) cell lines, respectively, were supplemented with FCS (10%), 
Pen/strep (1%) and L-glutamine (1%). Frozen muscle, pancreatic and liver cell lines were 
reconstituted in respective media and transferred into 25cm
3
 flasks which were incubated at 
37 
º
C in the presence of CO2 (5%) in a humidified (89%) incubator (Shel Lab, Cornelius, 
Oregon, USA). The cell lines were allowed to grow, attach and become confluent. The 
attached confluent cells were trypsinized with trypsin (0.25%) after washing three times with 
PBS. The cells were then sub-cultured in new flasks and incubated. Thereafter, the cell lines 
were plated in 24 and 96 well plates for experiments. To prepare doses required for each 
experiment, oxidovanadium complexes (1, 2 and 3) were freshly prepared in DMSO (0.1%) 
and subsequently diluted in fully supplemented respective cell culture media. Preliminary 
studies were undertaken to determine appropriate cell density, doses of drugs and time 
intervals for the study.  
 
2.2.4   Cell viability studies 
 
Cell viability studies were conducted in liver, muscle and pancreatic cell lines to examine the 
cytotoxic effects of oxidovanadium complexes. Cell viability was assayed using the Cell 
Titer-Glo Luminescent Cell Viability Assay Kit (Promega, Madison, Wisconsin, USA). The 
assay reagent produces luminescence in the presence of ATP from viable cells. The 
luminescence produced is proportional to the quantity of ATP present. The quantity of ATP 
is proportional to the amount of viable cells. The cell viability assay was conducted as 
follows; briefly, cells (10, 000 cells/mL) were seeded in 96-well plates and incubated in their 
respective media (200 µL) overnight. Thereafter the cells were treated with oxidovanadium 
complexes (12.5, 25 and 50 µg/mL).  Cells which were treated with DMSO (0.1%) , served 
as controls. Each treatment was conducted in 6 separate wells (n=6).  The combined 
treatment of oxidovanadium complexes (12.5μg/mL) with insulin (4μg/mL) or metformin 
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(160μg/mL) was also assessed on cell viability in liver and muscle cell lines. After 12, 24 and 
48 h, plates were equilibrated at room temperature for 30 min.  The assay reagent (100 µL) 
was added to each well, followed by shaking the plates for 2 min to induce cell lysis. After 
shaking, plates were incubated at room temperature for 10 min to stabilize the luminescence 
signal; thereafter the luminescence was read on the Promega microplate luminometer 
(Promega, Madison, Wisconsin, USA). For background correction, wells with medium only 
were used as blanks.. Data were expressed as percentage of viable cells (treatment value-
blank/ control value-blank×100%). For each time point (12, 24 and 48 h), the cell viability 
percentage was calculated based on the respective control. 
 
2.2.5   Glucose utilisation studies 
 
The glucose utilisation experiments were conducted as previously described by Ventera et al 
(2008) with slight modifications (Ventera et al., 2008). Separate 80% confluent liver and 
muscle cell lines (1.5 x10
5
) in 24 well plates were incubated at 37ºC with EMEM and 
DMEM (1 mL) containing 19 and 29 mmol/L of glucose, respectively, in the presence of 
various concentrations (12.5, 25 and 50 μg/mL) of oxidovanadium compounds (1, 2 or 3). 
Cells incubated with DMSO (0.1%) and insulin (4 µg/mL) or metformin (160 µg/mL) acted 
as untreated and treated positive controls, respectively. Each treatment was conducted in 6 
separate wells (n=6).. Media glucose concentrations were measured at 0, 12, 24 and 48 h with 
OneTouch select glucometer (Lifescan, Mosta, Malta, and United Kingdom).  
 
To examine the effects of combined treatments, a dose of 12.5 μg/mL of oxidovanadium 
complexes (1, 2 or 3) was combined with either insulin (4 µg/mL) or metformin (160 
µg/mL). This dose was the least effective in glucose utilisation and as a result this allowed 
observing whether combination with either insulin/metformin has positive additional effects 
on glucose utilisation. Media glucose concentrations were monitored as described above.  
After 48 h period, cells were trypsinised and harvested for measurements of glycogen and 








2.2.6   Glycogen assay 
 
Glycogen analysis was performed in liver and muscle cells harvested at 48 h. Glycogen assay 
was performed using a well-established laboratory protocol (Musabayane et al., 2005; 
Ngubane et al., 2011; Khathi et al., 2013).  The harvested muscle and liver cells were heated 
with KOH (30%, 2 mL) at 100ºC for 30 min. Thereafter, NaSO4 (10%, 0.194 mL) was added 
to stop the reaction and allowed to cool. For glycogen precipitation, the cooled mixture (200 
µL) was aspirated and mixed with ethanol (95%, 200 µL). The precipitated glycogen was 
pelleted, washed and resolubilized in H2O (1 mL). Thereafter, anthrone (0.5g dissolved in 
250ml of sulphuric acid, 4 mL) was added and boiled for 10 min. After cooling, the 
absorbance was read using the Spectrostar Nano spectrophotometer (BMG Labtech, 
Ortenburg, Baden-Württemberg, Germany) at 620 nm. The glycogen concentrations were 
calculated from the glycogen standard curve. The standards ranged from 200 to 1000 mg/L 
 
2.2.7   Insulin secretion studies  
 
Separate confluent pancreatic cells (1.5 x10
5
) in 24 well plates were incubated at 37ºC with 
RPMI (1 mL) containing 18 mmol/L of glucose, in the presence of oxidovanadium 
compounds (1, 2 or 3) (12 μg/mL). Each treatment was conducted in 6 separate wells 
(n=6).Cells incubated with DMSO (0.1%) untreated served as negative control, glucose 
concentrations were monitored 0, 12, 24 and 48 h.  The media samples were harvested at 12, 
24 and 48 h for insulin measurements. 
 
Media samples collected at 48 h period were assayed for insulin concentrations. Insulin was 
measured using ultra-sensitive rat insulin ELISA kit (DRG International, USA).  The kit 
contained a 96 well plate coated with mouse monoclonal anti-insulin, calibrator, enzyme 
conjugate, enzyme conjugate buffer, wash buffer, substrate 3,3',5,5'-tetramethylbenzidine 
(TMB) and a stop solution. The principle of the assay is a solid phase two-site enzyme 
immunoassay based on the direct sandwich technique in which two monoclonal antibodies 
are directed towards separate antigenic determinants on the insulin molecule. During the 
incubation period insulin in the sample reacts with peroxidase-conjugated anti-insulin 
antibodies and anti-insulin antibodies bound to the microtitration well. The washing step 
removes unbound enzyme labelled antibody, leaving the bound conjugate which reacts with 
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TMB. This reaction is stopped by adding acid to give a colorimetric endpoint that is read 
spectrophotometrically.  
 
Each determination was conducted in duplicate for both calibrators and samples. The insulin 
assay was performed as follows; calibrators (0, 3.40, 8.50, 25.50, 68.10 and 170.27 pmol/L) 
or samples (10 μL) were added in each well of the plate coated with anti-insulin antibody. 
Thereafter, an enzyme conjugate solution (100 μL) was added in each well, followed by 
incubation of the plate at room temperature on an orbital shaker for 2 hours. After incubation, 
the reaction volume was discarded followed by washing (5 times) using a wash buffer 
solution (350 μL) per well. After washing, a substrate TMB (200 μL) was added in each well 
and incubated for 15 min at room temperature. Thereafter, a stop solution (50 μL) was added in 
each well, followed by shaking for 5 seconds. The absorbance was read using a Spectrostar 
Nano spectrophotometer (BMG Labtech, Ortenburg, Baden-Württemberg, Germany) at 450 
nm. Sample insulin concentrations were extrapolated from the insulin standard curve. The 
lower and upper limits of detection were 1.39 and 960 pmol/L, respectively. The intra-assay 
analytical coefficient of variation ranged from 4.4 to 5.5% and the inter-assay coefficient 
variation from 4.7 to 8.9%. 
 
2.2.8   Western blot analysis 
 
 
The muscle and liver cells harvested at 48 h were examined for expression of GLUT4 and 
glycogen synthase, respectively. Cells (1 ×10
5 
cells/mL) were homogenized using a glass rod 
on ice in isolation buffer (0.5 mM Na2EDTA, 0.1 M KH2PO4, 0.1 mM dithiothreitol, 0.25 M 
sucrose) and then centrifuged at 400 x g for 10 min (4 °C). The supernatant was harvested 
and the protein content was quantified using the bicinchoninic acid assay (BCA) (Sigma-
Aldrich, St Louis, Missouri, USA). Briefly, the standards or samples (250 μL) were mixed 
with BCA working solution (200μl) in a 96 well plate.  Thereafter, the plate was incubated at 
37 Cº for 30 minutes, after cooling the absorbance was read at 562 nm. The protein 
concentrations were extrapolated from a protein standard curve (0.2-1 mg/mL). For Western 
blot analysis, all protein samples were standardized to (1 mg/mL). The proteins were then 
denatured by boiling in laemmli sample buffer (0.5 M Tris-HCl, glycerol, 10% SDS, 2 
mecarptoethanol, 1% bromophenol blue) for 5 min. The denatured proteins were loaded (20 
μL) on prepared resolving (10%) and stacking (4%) polyacrylamide gels along with 
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molecular weight marker (5 μL). The gels were electrophoresed for 1 h at 150 V in electrode 
running buffer (Tris base, glycine, SDS), pH 8.3). After electrophoresis, the resolved proteins 
were electro-transferred to an equilibrated polyvinylidene difluoride (PVDF) membrane for 1 
h in transfer buffer (192 mM glycine, 25 mM Tris, 10% methanol). Following transfer, the 
membranes were blocked with 5% non-fat dry milk in Tris-buffered saline with 0.1% Tween 
20 (TTBS) (20 mM Tris, 150 mM NaCl, KCl, 0.05% Tween-20). The membranes were then 
immuno-probed with antibodies- GLUT 4 and glycogen synthase (1:1000 in 1% TTBS) for 1 
h at room temperature. The PVDF membrane was then subjected to 5 washes (10 min each 
with gentle agitation) with TTBS. The membranes were then incubated in HRP-conjugated 
secondary antibody (rabbit anti-mouse 1:1000 in TTBS) for 1 h at room temperature. After 
washing, antigen-antibody complexes were detected by chemiluminescence using the 
Immune-star HRP substrate kit (Bio-Rad, Johannesburg, South Africa). Chemiluminescent 
signals were detected with the Chemi-doc XRS gel documentation system and analysed using 
the quantity one software (Bio-Rad, Johannesburg, South Africa). Band intensity analysis 
was conducted on the resultant bands. β-actin was used as reference protein and densitometry 
was expressed as band intensity of protein of interest over β- actin. 
 
 
2.2.9   Statistical analysis 
 
All data are expressed as means ± standard error of means (SEM). Statistical analysis was 
performed using GraphPad Prism Instat Software (version 5.00, GraphPad Software, San 
Diego, California, USA).  One-way analysis of variance (ANOVA) followed by Tukey-
Kramer was used for analysis of differences between control and experimental groups.  











      RESULTS 
 
3.1     Synthesis of oxidovanadium complexes 
The complexes cis-[VO2(Hpybz)(pybz)] (1), (µ-O)[VO(Hpybz)(pybz).VO(Hpybz)(acac)] (2)  
and [VO(Hpbyz)2SO4].H2O (3) were successfully synthesized and verified using the UV/Viz, 
NMR,  IR and ESR spectroscopy and crystal X-ray diffraction. Complexes 1, 2 and 3 were 
yellow cubic crystals, green thin needles and green cubic crystals, respectively. Furthermore, 
all complexes exhibited good solubility in high boiling points solvents and less solubility in 
alcohol and chlorinated solvents. 
 
3.2        Cell viability 
3.2.1      The effects of oxidovanadium complexes 
Figures 2 and 3 show the effects of oxidovanadium complexes on cell viability in liver cell 
and muscle cells.  The administration of lower doses (12.5 and 25 μg/mL) of oxidovanadium 
complex (1, 2 and 3) showed no toxic effects in comparison to the control at corresponding 
time intervals. However, the administration of high dose (50 μg/mL) showed a decrease in 
cell viability in comparison to the control at 24 and 48 h incubation period in both liver and 
muscle cells (Figures 2 and 3).  Figure 4 shows the percentage cell viability in pancreatic 
cells. There were no toxic effects in cells treated with low dose of oxidovanadium complexes 
(1, 2 and 3) in comparison to the control at corresponding time interval. However, there was a 
statistical significant decrease (p<0.05) on cell viability in cells treated with high doses of 
oxidovanadium complexes (1, 2 and 3) (Figure 4). 
 
3.2.2    The effects of oxidovanadium complexes combined with insulin 
Figures 5 and 6 show the effects of combined oxidovanadium (1, 2 and 3) and insulin 
administration on cell viability in liver and muscle cells. The combined treatment showed no 
toxic effects in both liver and muscle cells in comparison to the control. Furthermore, non-
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significant differences were observed between groups treated with combined treatment and 
oxidovanadium complexes or insulin alone after 12, 24 and 48 h (Figures 5 and 6) 
 
3.2.3    The effects of oxidovanadium complexes combined with metformin 
Figures 7 and 8 show the effect of administration of oxidovanadium (1, 2 and 3) combined 
with metformin on cell viability in liver and muscle cells. The combined treatment had no 
effects on cell viability in both liver and muscle cells in comparison to the control. 
Furthermore, non-significant differences were also observed between groups of combined 












































































Figure 3: The effects of oxidovanadium complexes on cell viability in liver cells after 12, 24 
and 48 h. Values are presented as means, and vertical bars indicate SEM (n=6 in each group).   


































































Figure 4: The effects of oxidovanadium complexes on cell viability in muscle cells after 12, 
24 and 48 h. Values are presented as means, and vertical bars indicate SEM (n=6 in each 










































































Figure 5: The effects of oxidovanadium complexes on cell viability in pancreatic cells after 
12, 24 and 48 h. Values are presented as means, and vertical bars indicate SEM (n=6 in each 



























































Figure 6: The effects of oxidovanadium complexes combined with insulin (V+Ins) on cell 
viability in liver cells after 12, 24 and 48 h. Values are presented as means, and vertical bars 



































































Figure 7: The effects of oxidovanadium complexes combined with insulin (V+Ins) on cell 
viability in muscle cells after 12, 24 and 48 h. Values are presented as means, and vertical 



























































Figure 8: The effects of oxidovanadium complexes combined with metformin (V+Met) on 
cell viability in liver cells after 12, 24 and 48 h. Values are presented as means, and vertical 

































































Figure 9: The effects of oxidovanadium complexes combined with metformin (V+Met) on 
cell viability in muscle cells after 12, 24 and 48 h. Values are presented as means, and 
vertical bars indicate SEM (n=6 in each group).    =p<0.05 by comparison with control 




3.3       Glucose utilisation 
 
3.3.1    Effects of oxidovanadium complexes  
Figures 9 and 10 show the effects of oxidovanadium complexes (1, 2 and 3) on glucose 
utilisation after 0, 12, 24 and 48 h in liver and muscle cells, respectively. The control groups 
for both muscle and liver cells showed a steady decline in glucose concentrations over 48 h 
experimental period. By comparison with the respective controls at corresponding time 
periods, the administration of the vanadium complexes (1, 2 and 3) significantly decreased 
(p<0.05) media glucose concentrations  with the lowest dose being the least effective in both 
liver and muscle cells after 12, 24 and 48 h incubation. Complex (2) showed to be the most 
effective oxidovanadium complex in reducing media glucose concentrations in both liver and 
muscle cells. The effects of oxidovanadium complexes (50 µg/mL) on glucose utilisation 
were comparable to insulin and more potent than metformin in both liver and muscle treated 
cells at all time points (Figures 9 and 10).   
 
3.3.2 Effects of oxidovanadium complexes combined with insulin.  
 
Figures 11 and 12 show the effects oxidovanadium complexes (1, 2 and 3) combined with 
insulin on glucose utilisation in both liver and muscle cells. By comparison with the 
respective controls at corresponding time periods, the administration of each combined 
treatment showed a statistical significant decline (p<0.05) in media glucose concentrations 
after 24 and 48 h in both muscle and liver cells (Figure 11 and 12). Furthermore, combined 
treatment of oxidovanadium complex (1) with insulin showed an added effects since there 
was significantly reduced (p<0.05) media glucose in comparison to oxidovanadium complex 
(1) or insulin alone, in muscle cells (Figure 12a).  
 
3.3.3      The effects of oxidovanadium complexes combined with metformin 
 
Figures 13 and 14 show the effects of oxidovanadium complexes (1, 2 and 3) combined with 
metformin on glucose utilisation in liver and muscle cells. By comparison with the respective 
controls at corresponding time intervals, the administration of each combined treatment 
showed a statistical significant decline (p<0.05) in media glucose concentrations after 24 and 
48 h in the muscle and liver cells. However, the administration of combined treatment 
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Figure 10: The effects of oxidovanadium complexes on glucose utilisation in liver cells after 
0, 12, 24 and 48 h. Values are presented as means, and vertical bars indicate SEM (n=6 in 








































































































Figure 11: The effects of oxidovanadium complexes on glucose utilisation in muscle cells 
after 0, 12, 24 and 48 h. Values are presented as means, and vertical bars indicate SEM (n=6 


























































































Figure 12: The effects of oxidovanadium complexes combined with insulin (V+Ins) on 
glucose utilisation in liver cells after 0, 12, 24 and 48 h. Values are presented as means and 
vertical bars indicate SEM (n=6 in each group).     =p<0.05 in comparison to the control 
























































































Figure 13: The effects of oxidovanadium complexes combined with insulin (V+Ins) on 
glucose utilisation in muscle cells after 0, 12, 24 and 48 h. Values are presented as means and 
vertical bars indicate SEM (n=6 in each group).    =p<0.05 in comparison to the control 
group, #=p<0.05 in comparison to insulin treated group and a=p<0.05 in comparison to 
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Figure 14: The effects of oxidovanadium complexes combined with metformin (V+Met) on 
glucose utilisation in liver cells after 0, 12, 24 and 48 h. Values are presented as means, and 
vertical bars indicate SEM (n=6 in each group).      =p<0.05 in comparison to the control 

















































































Figure 15: The effects of oxidovanadium complexes combined with metformin (V+Met) on 
glucose utilisation in muscle cells after 0, 12, 24 and 24 h.  Values are presented as means, 
and vertical bars indicate SEM (n=6 in each group).      =p<0.05 in comparison to the control. 





3.4         The effects of oxidovanadium complexes on glycogen synthesis 
Table 1 shows the effects of oxidovanadium complexes (50 μg/mL) (1, 2 and 3) and 
combined treatment administration on glycogen synthesis in both liver and muscle cells after 
48 h. The administration of oxidovanadium complexes (1, 2 and 3) significantly increased 
(p<0.05) glycogen concentrations in both liver and muscle cells in comparison to the control. 
Interestingly, the effects of oxidovanadium complex (2) were comparable to insulin treated 
groups in both liver and muscle cells. Furthermore, the administration of each combined 
treatment significantly increased (p<0.05) glycogen concentrations in both liver and muscle 
cells in comparison to the control. Administration of oxidovanadium complex (1) combined 
with insulin showed a statistically significant increase (p<0.05) in glycogen synthesis in 

















Table 1: The effects of oxidovanadium complexes and combined treatment on glycogen 
synthesis in liver and muscle cells after 48 h.  
 









Control 12.01±0.13 0.76±0.01 8.56±0.16* 0.64±0.07 
Complex (1) 2.10±0.23* 1.40±0.02* 2.24±0.72* 0.86±0.02* 
Complex (2) 1.06±0.25* 1.30±0.02* 1.25±0.24* 0.80±0.02* 
Complex (3) 4.20±0.21* 1.20±0.02* 2.12±0.24* 1.00±0.01* 
Insulin 2.20±0.23* 1.78±0.02* 2.42±0.30* 1.00±0.00* 
Metformin 6.80±0.43* 1.17±0.00* 4.90±1.09* 0.92±0.03* 
Complex (1)+Insulin 1.04±0.13*#a 1.91±0.02*#a 3.02±0.30* 0.90±0.04*  
Complex (2)+Insulin 3.20±0.31* 1.30±0.05* 3.02±0.28* 0.86±0.01* 
Complex (3)+ Insulin 3.50±0.21* 1.20±0.02* 3.18±0.52* 0.84±0.01* 
Complex 
(1)+Metformin 
6.10±0.23* 1.20±0.03* 3.90±0.29* 0.81±0.06* 
Complex 
(2)+Metformin 
6.14±0.43* 1.10±0.04* 3.50±0.33* 0.84±0.01* 
Complex 
(3)+Metformin 
6.50±0.42* 1.20±0.06* 3.40±0.22* 0.85±0.05* 
 
*= p<0.05 in comparison to the control 
 #=p<0.05 in comparison to oxidovanadium complex (1)  








3.5      Effects of oxidovanadium complexes on insulin secretion 
Table 2 shows the effects of oxidovanadium complexes (1, 2 and 3) (12.5 μg/mL) on insulin 
secretion in pancreatic cells after 12, 24 and 48 h. The administration of oxidovanadium 
complexes (1 and 3) had no effects on media glucose concentrations and insulin secretion in 
comparison to the control after 12, 24 and 48 h. However, administration of oxidovanadium 
complex (2) significantly decreased (p<0.05) media glucose concentrations with concomitant 




















Table 2: The effects of oxidovanadium complexes on insulin secretion in pancreatic cells 
after 12, 24 and 48 h. 
Groups Glucose (mmol/L) Insulin (pmol/L) 
                                                                             12 h 
Control 15.0±0.6 101.0±5.2 
Complex (1) 14.5±0.5 105.0±4.3 
Complex (2) 13.6±0.6 110.0±3.2* 
Complex (3) 14.5±1.0 98.0±4.1 
                                                                              24 h 
Control 13.2±0.8 131.0±6.1 
Complex (1) 13.9±0.2 129.0±3.9 
Complex (2) 10.2±0.7* 143.0±3.2* 
Complex (3) 13.1±0.5 138.0±4.5 
                                                                              48 h 
Control 11.5±0.5 191.0±2.4 
Complex (1) 11.5±0.2 191.0±2.4 
Complex (2) 7.8±1.00* 255.0±2.1* 
Complex (3) 11.5±0.3 191.0±3.1 
 








3.6         Western blots analysis 
The effects of highest dose (50 μg/mL) of oxidovanadium complex (2) were examined on 
glycogen synthase and GLUT4 in liver and muscle cells, respectively after 48 h. 
 
3.6.1       Glycogen synthase 
Figure 15 shows the effects of oxidovanadium complex (2) on glycogen synthase (GS) 
expression in liver cells. Administration of oxidovanadium complex (2) significantly 
increased (p<0.05) GS expression as indicated by increased densitometry in comparison to 
the control group (figure 15).   
 
3.6.2     GLUT4 
Figure 16 shows the effects of oxidovanadium complex (2) on GLUT4 expression in muscle 
cells. Administration of oxidovanadium complex (2) significantly increased (p<0.05) the 
expression of GLUT4 as indicated by increased densitometry in comparison to the control 














                 
























Figure 16: The effects of oxidovanadium complex (2) on GS expression in liver cells. 
Density of GS is expressed over β-actin. Values are presented as means, and vertical bars 
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Figure 17: The effects of oxidovanadium complex (2) on GLUT4 expression in muscle cells. 
Density of GLUT4 is expressed over β-actin. Values are presented as means, and vertical bars 
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The aim of the study was to synthesise and characterise the novel oxidovanadium complexes, 
and to investigate the effects of novel oxidovanadium complexes on glucose utilisation in 
liver and skeletal muscle cells and insulin secretion in pancreatic cells. The oxidovanadium 
complexes were synthesized and further verified using physical and chemical characteristics. 
The observations in cell viability studies suggested that lower doses of oxidovanadium had 
no cytotoxic effects in both liver and muscle cells. However, for the pancreatic cells, only 
lowest dose had no cytotoxic effects. Oxidovanadium complexes increased glucose uptake in 
both liver and muscle cell lines mediated perhaps via enhanced glycogen synthesis. The 
observations of the current study therefore extend literature reports where various vanadium 
complexes have been shown to possess anti-hyperglycaemic properties (Cohen et al., 2001; 
Willsky et al., 2011; Shehzad, 2013).  Of the complexes studied only oxidovanadium 
complex (2) increased insulin secretion in pancreatic cell line suggesting that further studies 
are required on the effects of oxidovanadium complexes on insulin secretion. The ability of 
oxidovanadium complex (2) to promote both glucose disposal and insulin secretion suggests 
that this compound may ensure tight glycaemia in vivo.  These observations may also be of 
clinical relevance considering the morbidity together with the burden exerted by diabetes in 
health systems and facilities. 
 
Cell viability studies were undertaken to determine whether oxidovanadium complexes 
possess any cytotoxic effects.  The effects of oxidovanadium complexes were investigated on 
cell viability in liver, muscle and pancreatic cell lines. There were no apparent cytotoxic 
effects after lower doses of oxidovanadium complexes administration in both liver and 
muscle cell lines. However, the dose of 50μg/mL administration showed a decline in cell 
viability, indicating cytotoxic effects, which may be due to oxidative stress elicited by 
oxidovanadium complexes. The increase in cell viability seen at 12 h may be due to 
proliferative effects of oxidovanadium complexes; however, we may not exclude other 
possibilities. Furthermore, there were no cytotoxic effects observed when the lowest dose of 
oxidovanadium was combined with either insulin or metformin. However, further studies are 
needed to determine whether insulin or metformin may correct the negative effects elicited by 
high doses in both liver and muscle cells. Administration of high doses of oxidovanadium 
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complexes, however, had cytotoxic effects to the pancreatic cell line as evidenced by a sharp 
decline in cell viability. Some vanadium complexes such vanadyl sulphates, sodium 
orthovanadate and vanadyl organic complexes have been reported to promote free radicals 
formation in biological systems  (Zhao et al., 2009). On the other hand, pancreas islets have 
been reported to have little amounts of antioxidants to neutralize free radicals formation 
(Kubisch et al., 1997). Therefore, the reduced cell viability in pancreatic cells after 
oxidovanadium complexes administration may be attributed to oxidative stress. Oxidative 
stress has been shown to promote lipid peroxidation and DNA damage which is known to 
promote cell death mechanisms such as apoptosis (James et al., 2002). However, we may not 
exclude other mechanisms and thus the mechanisms through which complexes exert toxicity 
in pancreatic cells remain unclear. Due to significant toxicity elicited by higher doses in 
pancreatic cells, only lowest dose was used to study the effects of oxidovanadium complexes 
on insulin secretion. 
 
Anti-hyperglycaemic effects of various vanadium complexes have been investigated using 
chemically induced-diabetic models. However, biological tests in whole animal have been 
found to be expensive, time consuming and have a limited sensitivity to differentiate between 
structurally similar compounds. In this study, the yield of oxidovanadium complexes was 
very low and thus their effects on glucose utilisation and insulin secretion were only limited 
to in vitro studies. Muscle and liver tissues play a significant role in glucose homeostasis. 
Furthermore, glucose metabolism in these tissues is also controlled by insulin and various 
drugs have been shown to influence glucose metabolism in these tissues. Moreover, literature 
evidence indicates that muscle and liver cells are extensively employed in glucose 
metabolism research. Yen et al has demonstrated that the cinnamon extract promotes glucose 
uptake in muscle (C2C12) cells (Yen et al., 2014). Resveratrol has  also been shown to 
promote glucose uptake through adenosine monophosphate protein kinase  (AMPK) pathway 
in C2C12 cells (Chang et al., 2009). On the other hand, Nadu has shown that sex steroids 
increase glucose uptake in liver (Chang) cells (Nadu, 2007). Therefore, the liver (Chang) and 
muscle (C2C12) cells are significant tools in investigating the effects of a particular 
compound on glucose metabolism.  For these reasons, liver (Chang) and muscle (C2C12) 
were chosen to investigate the effects of oxidovanadium complexes on glucose metabolism. 
In this study, the doses of drugs, glucose concentrations and time intervals were determined 
from a series of preliminary studies.   For glucose utilisation experiments, a decline in media 
55 
 
glucose indicated an increase in glucose uptake by the cells. The poor glucose uptake 
observed in the control muscle cells was due to the lack of insulin.  The glucose uptake 
observed in the muscle cells may be attributed to the basal glucose uptake, mainly facilitated 
by GLUT1 which has been reported to be present in almost all tissues (Ciaraldi et al., 2005). 
In the liver control cells, the steady decline in media glucose may be attributed to the 
presence of a bidirectional GLUT2 which facilitates glucose uptake into the liver cells 
(Weinstein et al., 1994). Insulin administration in both liver and muscle cells increased 
glucose uptake as evidenced by a sharp decline in media glucose concentrations. Insulin 
facilitates glucose uptake in the muscle and adipose through GLUT4 translocation and 
enhanced glycogen synthesis (Withers et al., 1998). In the liver cells glucose uptake is 
independent of insulin and there are no drugs which have been found to directly influence 
glucose uptake (Postic et al., 1993). However, insulin promote glucose uptake indirectly via 
increasing glycogen synthesis. Administration of oxidovanadium complexes significantly 
improved glucose uptake in both liver and muscle cells suggesting insulin mimetic effects.  
Several vanadium based compounds have been demonstrated to promote glucose uptake in 
vitro.  A study by Mendes et al has also shown that vanadium complexes such vanadate 2-
pyrideneformamide thiosemimacarbozones enhance glucose uptake in adipocytes (Pariente et 
al., 1999). Furthermore, insulin or oxidovanadium complex (2) increased GLUT4 expression 
in muscle cells which may explain an increase in glucose uptake observed in the muscle cells. 
These observations are in agreement with the literature reports since some studies have 
shown elevated GLUT4 expression after vanadium administration (Li and McNeill, 2001; 
Mohammad et al., 2002). In the absence of insulin, GLUT4 is trapped within the cysotol 
vesicles and GLUT4 translocation is influenced by insulin and other diverse signals  (Nia et 
al., 2002; Sano et al., 2008). Upregulation of GLUT4 expression is critical for glucose uptake 
and a decreased GLUT4 expression has been reported in diabetes (Gaster et al., 2001).  A 
novel compound that has the ability to increase GLUT4 expression in muscle or adipose 
tissue is regarded as beneficial in the management of diabetes.  The mechanisms through 
which our oxidovanadium complexes promote glucose uptake and GLUT4 expression cannot 
be explained by the present study. We speculate that our oxidovanadium complexes may 
facilitate glucose uptake partly through AMPK pathway activation. AMPK is a 
phylogenetically conserved serine/threonine kinase which functions independent of insulin. 
Activation of AMPK has been reported to increase glucose uptake through increased 
expression of GLUT4, hexokinase and enhanced glycogen synthesis via Akt pathway 
(Sakamoto and Holman, 2008). Furthermore, some anti-diabetic agents such as biguanides 
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and TZDs have been reported to target AMPK (Shaw et al., 2005). In this study, metformin 
also had positive effects in the absence of insulin in both liver and muscle cells. Apart from 
AMPK, some anti-hyperglycaemic drugs interact with PPRγ to promote glucose disposal in 
the muscle and adipose. The ability of oxidovanadium complexes to influence glucose uptake 
in both muscle and liver cells may be of a beneficial feature in improving glucose 
homeostasis. Glucose homeostasis improvement is essential and is regarded as the primary 
intervention in the management of diabetes to delay the onset or the progression of diabetes 
complications. In addition to insulin, conventional anti-hyperglycaemic drugs such as 
metformin and rosiglitazone achieve their effects through enhancing glucose disposal in liver 
and muscle (Lebovits, 2002; Ohiraa et al., 2007).  
After glucose has entered the liver or muscle cell, glucose is metabolized by various 
metabolic pathways. Upon entry to the cells, glucose is converted to glucose-6-phosphate 
which is then metabolised via glycolysis, citric acid cycle and oxidative phosphorylation to 
form ATP required for cell metabolic processes (Guoa et al., 2012). The citric acid cycle 
intermediates are shunted towards lipid synthesis which is under insulin control in the liver, 
muscle and adipose (Inzucchi et al., 2002). Furthermore, glucose is stored as glycogen in the 
liver and muscle, a metabolic process which is also influenced by insulin signaling (Aronson 
and Rayfield, 2000). In this study, we also investigated the effects of oxidovanadium 
complexes on glycogen synthesis as one of the mechanisms involved in glucose disposal. 
Both muscle and control liver cells showed poor glycogen synthesis perhaps due to lack of 
insulin. Furthermore, these observations correlated with reduced expression of glycogen 
synthase in control liver cells. Insulin is known to promote glycogen synthesis in both liver 
and muscle cells (Vollenweider, 2003). An increase in glycogen synthesis observed after 
oxidovanadium complexes administration may also explain or support the increase in glucose 
uptake observed in both liver and muscle cells. The increase in glycogen synthesis may be 
partly mediated via glycogen synthase expression which was also found to be elevated in 
liver cells. Our observations on glycogen levels slightly deviate from the literature perhaps 
due to different assays employed.  Furthermore studies have reported correlation between 
glycogen synthesis and glycogen synthase expression in vitro which we also observed in this 
study (Mamedova and Shneyvays, 2003; Vigoda et al., 2003). We speculate that the effects 
of oxidovanadium complexes on glycogen synthesis were partly mediated via activation of 
AMPK and Akt downstream effectors. Physiologically, GS expression is modulated by 
insulin or AMPK through PI3-K activation which further activates GS3-K to enhance GS 
57 
 
expression for glycogen synthesis (White, 2003).  For these reasons, we speculate that our 
oxidovanadium complexes may act upstream PI3-K. Some vanadium complexes have been 
shown to enhance the fore mentioned metabolic process such as glycogen synthesis both in 
vitro and in vivo (Reul et al., 1999). Vanadium complexes such bisperoxovanadate have been 
demonstrated to increase glycogen synthesis in fibroblast cells (Schmid et al., 2004). Studies 
by Tolman also demonstrated that vanadium based compounds increase glucose uptake with 
concomitant increase in glycogen synthesis in the liver (Tolman et al., 2000). A study by 
Furnsim et al   has also demonstrated an increase in glycogen synthesis in rat isolated muscle 
after vanadium complex administration (Furnisim et al., 2001). Since the causal link of DM 
and associated complications is hyperglycaemia, the ability of a novel agent to efficiently 
lower blood glucose concentrations or facilitate glucose disposal is of importance in diabetes 
therapy. 
 
Furthermore, in this study we observed that the overall potency in glucose uptake by 
oxidovanadium complexes (high dose) was comparable to insulin. These observations 
together with enhanced glycogen synthesis and expressions of GLUT4 and GS may suggest 
that our oxidovanadium complexes mimic insulin’s actions and may utilize the same or 
similar mechanisms as insulin to facilitate glucose disposal. The mechanisms through which 
vanadium enhance glucose disposal are not well-understood.  Some mechanisms that have 
been reported involve activation of non-receptor cytosolic protein and inhibition of 
phosphotyrosine kinase phosphatases in the muscle. Inhibition of phosphotyrosine kinase 
phosphatases by vanadium complexes was found to enhance glucose uptake together with 
glycogen synthesis (Schmid et al., 2004). Furthermore, inhibition of this enzyme by 
bismaltolato oxovanadium was found to increase the tyrosine kinase activity, leading to 
enhanced insulin sensitivity in muscle tissue (Bhattacharyya and Alan, 2001). For these 
reasons, further studies are required to elucidate the mechanisms through which our novel 
oxidovanadium complexes exert their effects on glucose metabolism in both liver and muscle 
cells.  
 
Structurally different vanadium complexes have been demonstrated to have anti-
hyperglycaemic and beneficial effects in vivo. Studies have shown that oral vanadyl sulphate  
administration increased hepatic and peripheral insulin sensitivity in patients with type 2 DM 
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(Cohen et al., 2001).   Studies by Subramanian et al in STZ-induced diabetic rats showed that 
a non-toxic vanadium-3-hydroxyflavone complex  has anti-diabetic properties associated 
with improved lipid profile (Subramanian et al., 2014).  Willsky et al has demonstrated that 
vanadium dipicolinate administration normalizes hyperglycaemia and hyperlidaemia in obese 
rats (Willsky et al., 2011). Crans also investigated the effects of vanadium (IV) and (V) 
compounds and found that they had a long term insulin mimetic effects in vivo (Crans, 2000). 
For these reasons, we envisage that our novel oxidovanadium complexes may have positive 
effects in improving glucose homeostasis in diabetes. 
 
To date, the potency of vanadium complexes combined with anti-hyperglycaemic agents 
remains controversial. Studies have documented that vanadium complexes combined with 
insulin or TZDs had no additive blood glucose lowering effects (Storr et al., 2003). We also 
went a further step and investigated the effects of oxidovanadium complexes combined with 
insulin or metformin on glucose utilisation and glycogen synthesis in both liver and muscle 
cells. Our results are also controversial since only oxidovanadium complex (1) combined 
with insulin showed enhanced potency in both glucose utilisation and glycogen synthesis in 
the muscle cells. The enhanced potency may be possibly due to enhanced insulin sensitivity 
in the muscle after a combined treatment administration.  Some vanadium complexes have 
been shown to influence insulin sensitivity in peripheral tissues (Srivastava and Mehdi, 
2005). We speculate that our oxidovanadium complex (1) may sensitize insulin receptors to 
insulin. However, there is also a possibility that the synergistic effects observed may be due 
to more than one mechanism involved in glucose uptake after combined treatment 
administration. Furthermore, combining oxidovanadium complexes with metformin did not 
show positive synergistic effects. Metformin is known to have permissive effects to insulin 
through sensitizing insulin receptors. These observations may suggest that oxidovanadium 
complexes act downstream insulin receptor, possibly through interacting with tyrosine kinase, 
IRS-1 or PI-3K directly. Woo et al  also studied the blood glucose lowering effects of 
vanadyl-biguanide compounds on STZ-induced diabetic rats and no apparent synergistic 
positive effects were observed (Woo et al., 1999). 
 
The ability of a compound to promote insulin secretion is beneficial in the management of 
type 2 diabetes. In this study, we also investigated the effects of oxidovanadium complexes 
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on insulin secretion in pancreatic (RIN-5) cells. The RIN-5 cells have been reported to 
secrete substantial amounts of insulin, in addition to small amounts of glucagon and 
somatostatin (Poitout et al., 1996; Fernández-Millán et al., 2014). Furthermore, literature 
indicates that RIN-5 cells are among the widely used cell lines in studying insulin secretion 
(Polina et al., 2010; Gorelick et al., 2011). Studies by Gorelick et al and Polina et al have 
demonstrated that administration of plant extracts increase insulin secretion by RIN-5 cells 
(Polina et al., 2010; Gorelick et al., 2011). In this study, RIN-5 cells were chosen to 
investigate the effects of oxidovanadium complexes on insulin secretion.  In control cells, we 
observed presence of insulin which was secreted into the media, probably due to presence of 
glucose.  The β-cells are electrically excitable and transition in the membrane potential 
coupled to plasma glucose concentration variations stimulate or inhibit insulin secretion 
(Ashcroft and Rorsman, 1989). In vitro, in response to glucose challenge, from about 1-20 
mM, insulin secretion increase about 15-folds (Henquin, 2000).  Therefore, glucose 
concentrations play a well-understood significant role on insulin secretion by the β-cells. The 
entry of glucose in the β-cells through GLUT2 leads to changes in the ATP/ADP ratio with 
subsequent activation of ATP dependent K
+
 channels and opening of Ca
2+
 channels (Donald 
et al., 2013). Following successive events, insulin is released by Ca
2+
 dependant exocytosis 
through secretory granules which fuse with the cell membrane (Ammala et al., 1993).   
Studies have documented that vanadium complexes such as bis-maltolato vanadium and 
vanadate pyrrolodine-N-dithiocarbamate increase insulin secretion in experimental animals 
(Conconi et al., 2003). In spite of these observations, there have been no consensus 
mechanisms given. Our observations on insulin secretion in the pancreatic cells remain 
controversial since only oxidovanadium complex (2) increased insulin secretion. The increase 
in insulin secretion correlated with an increase in glucose uptake by the pancreatic cells. 
However, the mechanisms through which these observations occurred may not be explained 





 channels since they play a crucial role on insulin secretion. 
Therapeutic modalities that affect insulin secretion such as sulphonylurea have been shown to 
activate ATP dependent K
+
 channels (Fuhlendorf et al., 2001). Furthermore, Pariente et al 
has shown that vanadate compounds promote Ca
2+
 mobilization and Ca
2+
 influx in pancreatic 
acinar cells (Pariente et al., 1999).  Apart from well-known mechanisms, our oxidovanadium 
complex may also interact with SNARE proteins which have been reported to be involved in 
insulin secretion.  Some studies have shown that interfering with SNARE proteins influence 
insulin secretion. SNARE phosphorylation has been shown to play a significant role in 
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modulating the secretory capacity of β-cells (Seino and Shibasaki, 2005). Furthermore, 
studies have also reported that overexpression of SNARE leads to cAMP dependant 
exocytosis of insulin from secretory granules (Barnard et al., 1997). For these reasons, further 
studies are required to investigate the exact mechanisms through which our oxidovanadium 
























 5.0  Conclusions 
Oxidovanadium complexes (1, 2 and 3) enhance glucose metabolism in both liver and muscle 
cell lines in vitro. Furthermore, the effects of oxidovanadium complexes on insulin secretion 
remain controversial in pancreatic cells. The ability of oxidovanadium complexes to 
independently promote glucose metabolism in the liver and muscle may be beneficial in the 
management of both type 1 and type 2 diabetes. The overall observations warrant further 
investigations in a rat model to determine whether complex 2 might exert a tight glycaemic 
control in vivo.  
 
5.1  Limitations  
In the current study we did not investigate the blood glucose lowering effects of 
oxidovanadium complexes and effects on insulin secretion in vivo. 
 
5.2  Recommendations for future studies 
The observations of the current study highlight the significance to further evaluate the effects 
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Appendix I: Conference presentations 
(a) Poster presentation titled “The effects of Syzygium aromaticum-derived-oleanolic acid (OA) 
on reactive oxygen species in the heart, liver and kidneys of STZ-induced diabetic rats” was 
delivered in the Society for Endocrinology BES 2013 (21 March 2013) 





(b) Oral presentation titled “Antioxidant effects of oleanolic acid in livers, hearts and 
kidneys of streptozotocin-induced diabetic rats” was delivered in Physiological Society of 




ANTIOXIDANT EFFECTS OF OLEANOLIC ACID IN LIVERS, HEARTS AND KIDNEYS 







Rene Myburg & 
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Cephas T Musabayane   
School of Laboratory Medicine and Medical Sciences, Disciplines of 
1
Human Physiology & 
2
Biochemistry, College of Health Sciences, University of KwaZulu- Natal, Private Bag X54001, 
Durban 4000, South Africa 
 
Hyperglycaemia-induced oxidative stress triggers the development and progression of microvascular 
and macrovascular complications in diabetes.  However, some plant extracts containing quercetin, 
flavonoids and triterpenes decrease blood glucose concentrations and oxidative stress in experimental 
diabetes. Hence we postulated that the triterpene oleanolic acid (OA) which possesses anti-
hyperglycaemic properties can prevent oxidative stress to consequently avert complications in 
diabetes. This study was, therefore, designed to investigate the effects of Syzygium aromaticum-
derived OA on oxidative stress in the hepatic, renal and cardiac tissues of streptozotocin (STZ)-
induced diabetic rats. Pectin hydrogel OA patches were applied on shaved back of the neck of STZ-
induced diabetic rats, twice after every third day, for five weeks. Pectin free OA patch and insulin 
subcutaneously administered rats served as untreated and treated positive controls while non-diabetic 
untreated rats served as negative controls. After five weeks, animals were sacrificed followed by 
measurement of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase 
(GPx) in the hepatic, cardiac and renal tissues. Topical OA administration significantly reduced MDA 
levels in the hepatic, renal and cardiac tissues of STZ-induced diabetic rats with concomitant increase 
of the concentration of antioxidant enzymes, SOD and GPx. These results suggest that OA 
ameliorates oxidative stress in the liver, heart and kidneys and this may consequently avert 
macrovascular and microvascular complications of DM.  It can thus be concluded that OA is a 











(c) Poster presentation titled “Evaluation of the effects of oxidovanadium 2-
pyridylbenzimidazole (Hpybz) compounds on glucose metabolism in liver and skeletal muscle 
cell lines” was delivered in the Society of Endocrinology (1 July 2014) 






(d) Oral presentation titled “The effects of vanadium complexes on insulin secretion in 
pancreatic cell lines” was delivered in the College of Health Sciences Research Symposium 
(11-12 September 2014). 
 
THE EFFECTS OF VANADIUM COMPLEXES ON INSULIN SECRETION IN 
PANCREATIC CELL LINES 
Mfayela N, Sibiya N.H, Serumula M.R and Musabayane C.T  
School of Laboratory Medicine and Medical Sciences 
 
Vanadium complexes possess anti-hyperglycaemic properties but their mechanisms of action 
remain unclear. Accordingly, the study was designed to investigate the effects of vanadium 
complex 2-pyridylbenzamadizole acetylacetone oxovanadium Hpybz vo (acac) 2 on insulin 
secretion and furthermore investigate glucose utilization in vitro. The study was carried out 
using a well-established cell culture protocol. Separate preparations of  pancreatic and 
skeletal muscle cell lines were incubated with Roswell Park Memorial Institute and Dulbecco 
Minimal Essential Media containing 18 and 29 mmol/L of glucose respectively in the 
presence of hbypzvo(acac)2 (12, 25 and 50µg/mL). Dimethyl sulphoxide (0.1%) treated cells 
served as a control. Glucose concentrations and cell viability were monitored at specific time 
intervals (12, 24 and 48 hours). Thereafter, muscle cells were harvested for glycogen analysis 
and media samples of the pancreatic cell lines were collected for insulin measurements. The 
highest dose was more effective in eliciting glucose utilization in the skeletal muscle. This 
was associated with concomitant increase in glycogen synthesis. This can be seen with the 
glucose concentrations in comparison with the control (12.00±0.05 vs 1.00±0.05mmol/L) 
with concomitant increase in glycogen synthesis (0.76±0.02 vs 1.35±0.02mmol/L). 
Furthermore, hbypzvo (acac) 2 (12.5µg/mL) significantly (p<0.05) increased insulin 
secretion in comparison with the control (0.19±0.01 vs 0.23±0.01nmol/L). This vanadium 
compound showed no toxic effects in both muscle and pancreatic cell lines. These results 
suggest that the anti-hyperglycaemic effects of hbypzvo (acac) 2 may be exerted via 
enhanced glucose uptake in the skeletal muscle and insulin secretion in the pancreas. 










(e) Oral presentation titled “The effects of vanadium complexes combined with 
hypoglycaemic agents on glucose utilisation in the liver and muscle cell lines” was 














THE EFFECTS OF VANADIUM COMPLEXES COMBINED WITH 
HYPOGLYCAEMIC AGENTS ON GLUCOSE UTILISATION IN THE LIVER 
AND MUSCLE CELL LINES 
Z.P Mvelase, N.H Sibiya, M.R Serumula and C.T Musabayane 
School of Laboratory Medicine and Medical Sciences 
 
Studies in our laboratory have shown that 2-pyridylbenzimidazole dioxovanadium 
complex (hpybz (VO) 2) enhance glucose metabolism in the liver and skeletal muscle cell 
lines.However, the effects of hpybz (VO)2 with other hypoglycaemic agents is unknown. 
Accordingly, this study investigated the effects of 2 hpybz (VO) 2 complex in combination 
with metformin and insulin on glucose utilization in liver and muscle cell lines. The hpybz 
(VO) 2 (12.50 μg/mL) was combined with either insulin (4 μg/mL) or metformin (160 
μg/mL). Glucose concentrations were monitored at 0, 12, 24 and 48 hours. Thereafter, 
cells were harvested for glycogen analysis. By comparison to the control, hpybz (VO) 2 
combined with insulin significantly decreased media glucose in both liver (13.60±0.26 vs 
4.90±1.15mmol/L) and muscle cell lines (16.33±0.52 vs 5.00±0.73mmol/L) with 
concomitant increase in glycogen synthesis in both liver (1.70±0.02 vs 0.76±0.02mmol/L) 
and muscle cell lines (1.93±0.02 vs 0.76± 0.02mmol/L). Interestingly, an insulin combined 
treatment showed a significant additive effect on glucose utilization and glycogen 
synthesis when compared to hpybz (VO) 2 or insulin alone, in both liver and muscle cell 
lines. These results suggest that a combination administration of hpybz (VO) 2 with insulin 
is effective in glucose utilisation compared to a single drug administration in liver and 
muscle cell lines, in vitro. Therefore, administration of hpybz (VO) 2 in combination with 
insulin may be beneficiary in the management of diabetes mellitus. 
 
 
 
 
 
 
 
 
 
 
 
